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Joseph Emil Rupert 
 
TUMOR, FAT AND SKELETAL MUSCLE CROSSTALK VIA IL-6R TRANS-
SIGNALING MEDIATES PANCREATIC CANCER CACHEXIA 
 
Cachexia, the involuntary loss of fat and muscle is associated with 
pancreatic ductal adenocarcinoma (PDAC), contributing to its 90% 5-year 
mortality rate. Elevated Interleukin-6 (IL-6) expression is associated with 
cachexia severity and reduced survival in patients. IL-6 in cancer is well 
documented, but IL-6 signaling crosstalk among tissues is not. IL-6 signals by 
binding membrane-bound IL-6 receptor (IL-6R) (classical signaling) or soluble IL-
6R (sIL6R; trans-signaling) produced by shedding of the membrane receptor 
primarily from muscle, liver and leukocytes. Herein I investigate the role of tumor-
derived IL-6 on muscle and fat crosstalk in PDAC. Loss of IL-6 expression in 
murine KPC PDAC cells was accomplished by CRISPR/Cas9 mutagenesis of the 
Il6 gene. Orthotopic KPC IL-6 knockout (KPC-IL-6KO) tumor-bearing mice had 
reduced cachexia, with attenuated fat loss and no significant muscle loss, and 
longer survival versus KPC controls. Only KPC tumor-bearing mice had 
significant myosteatosis, aberrant branched chain amino acid and fatty acid 
metabolism, and reduced pyruvate entry into the TCA-cycle, determined by 
increased pyruvate dehydrogenase kinase 4 (PDK4) expression in muscle. 
Muscle was a main source of sIL6R, and fat a primary contributor of IL-6 in KPC 
tumor-bearing mice. Myosteatosis leads to activation of lipid-sensitive kinases 
like protein kinase C theta (PKCθ, gene name Prkcq) in muscle. KPC tumor-
bearing mice had increased muscle PKCθ activation, and PKCθ is known to 
	 	 vi 
regulate metabolism and inflammation. Prkcq-/- KPC tumor-bearing mice had 
reduced cachexia and maintained muscle mass and force production versus wild 
type tumor-bearing mice. Together these data implicate progressive signaling 
mechanisms whereby tumor-derived IL-6 is associated with increased muscle 
IL6R expression and fat lipolysis, promoting myosteatosis and muscle PKCθ 
activation, ultimately increasing cachexia severity in PDAC. 
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CHAPTER 1: INTRODUCTION 
1.1 Cachexia 
Cachexia is a multifactorial syndrome characterized by the involuntary 
loss of adipose and muscle tissues (Fearon et al., 2011). Cachexia is a long-
recognized condition with written descriptions of the disease dating to ancient 
Greece. While some of the most severe cachectic phenotypes occur with cancer, 
multiple pathologies are associated with cachexia including sepsis, burn injury, 
polytrauma, HIV/AIDS, and chronic kidney disease (Argiles, Busquets, Stemmler, 
& Lopez-Soriano, 2015; Cohen, Nathan, & Goldberg, 2015). Notably, while 
wasting attributed to caloric restriction such as fasting, anorexia, or starvation 
can be reversed with feeding, dietary interventions are unsuccessful for 
improving patients with cachexia (Strohle, Zanker, & Hahn, 2010). This inability 
to be reversed with feeding categorically separates cachexia as an independent 
condition from other forms of wasting. Furthermore, ongoing investigation has 
revealed the important roles of inflammation, tissue dysmetabolism, and the 
central nervous system play in cachexia (Baracos, Martin, Korc, Guttridge, & 
Fearon, 2018; Burfeind et al., 2018; Pin, Barreto, Couch, Bonetto, & O'Connell, 
2019; VanderVeen, Fix, & Carson, 2017). Collectively, these studies elucidate 
the complexity of cachexia as an intricate network of tissue crosstalk acting in 
concert to significantly alter multiple biological processes. Of the multiple 
inflammatory cytokines expressed during cachexia, IL-6 is one of the most well-
known for inciting the severity of the disease. However, the effects of tumor-
derived versus host-derived IL-6 in cachexia and the nature of its crosstalk 
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between affected organs remains unclear. Thus, here I investigate cachexia as it 
pertains to pancreatic ductal adenocarcinoma (PDAC) and aim to determine the 
effects of tumor-derived IL-6 on inflammation, skeletal muscle and adipose tissue 
crosstalk via IL-6 signaling, and alterations in skeletal muscle metabolism. 
 
1.2 The IL-6 Signaling Pathway 
IL-6 initiates signal transduction by first binding to either the membrane-
bound form of the interleukin-6 receptor (IL6R), also known as glycoprotein 80 
(GP80), or its soluble form (sIL6R) (Schaper & Rose-John, 2015). While 
alternative splicing can produce sIL6R, the predominant source of circulating 
sIL6R appears to be proteolytic cleavage at the membrane from tissues 
expressing IL6R, resulting in a 55 kDa extracellular fragment (Schaper & Rose-
John, 2015). This activity is mediated in part through intracellular accumulation of 
phorbol esters, diacylglycerol (DAG), and subsequent activation of protein kinase 
C theta (PKC-q) (Mullberg, Schooltink, Stoyan, Heinrich, & Rose-John, 1992). 
Both complexes, IL-6 with membrane IL6R or with sIL6R, bind the ubiquitously 
expressed co-receptor IL-6 signal transducer (IL6ST), also known as 
glycoprotein 130 (GP130). The activity elicited by IL-6 and membrane IL6R is 
termed classical or cis signaling, while activity instigated by IL-6 with sIL6R is 
known as trans-signaling. Formation of either complex leads to trans-
phosphorylation and activation of Janus kinases (JAKs), which phosphorylate the 
transcription factor Signal Transducer and Activator of Transcription 3 (STAT3), 
promoting STAT3 dimerization and translocation to the nucleus (Taniguchi & 
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Karin, 2014), among other pathways. Unlike GP130, IL6R expression is not 
ubiquitous across cell types; thus, sIL6R trans-signaling allows for IL-6 signaling 
in IL6R negative cells (Rosean et al., 2014). Signaling through the membrane 
receptor is largely beneficial, while trans-signaling is generally pathological 
(Schaper & Rose-John, 2015). A growing number of studies suggest that 
neutralization of IL6R could have greater utility versus targeting IL-6 directly 
(Kraakman et al., 2015).  
 
1.3 The Effects of IL-6 Signaling in Skeletal Muscle 
 Skeletal muscle consists of multinucleated myofibers organized into 
fascicles, which are surrounded by the perimysium, a connective tissue layer that 
maintains fascicle structural integrity while also physically joining fascicles 
together. Dispersed in the extracellular matrix between myofibers are diverse 
groups of cells that include resident and infiltrating myeloid cells, fibroblasts, and 
myogenic stem cells termed satellite cells. Healthy muscle generally undergoes 
little remodeling; however, injured muscle has the capacity to rapidly regenerate 
(Ciciliot & Schiaffino, 2010; Dueweke, Awan, & Mendias, 2017; Hardy et al., 
2016). Muscle regeneration involves the precise coordination of both myofiber 
degradation (atrophy) and myofiber enlargement (hypertrophy). IL-6 plays a key 
role in both muscle hypertrophy and atrophy (Bian et al., 2017; Haddad, Zaldivar, 
Cooper, & Adams, 2005; Madaro et al., 2018; Mitchell et al., 2013; Munoz-
Canoves, Scheele, Pedersen, & Serrano, 2013; Rong, Bian, Hu, Ma, & Zhou, 
2018; Washington et al., 2011). The concentration of IL-6 and signaling method 
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(ie, autocrine vs paracrine) produces very different downstream effects. For 
instance, exercise induces acute elevations in muscle IL-6 production, 
subsequently increasing plasma IL-6 levels and influencing paracrine signaling 
by increasing adipose tissue lipolysis; this autocrine IL-6 signaling on muscle is 
beneficial for muscle hypertrophy and reestablishing metabolic homeostasis after 
exercise (Ikeda et al., 2016; Knudsen et al., 2017; Peake, Della Gatta, Suzuki, & 
Nieman, 2015; Pedersen, Steensberg, & Schjerling, 2001). In contrast, chronic, 
high levels of plasma IL-6 like those observed during inflammation have 
detrimental effects on muscle and are largely associated with atrophy (Byun, 
Cho, Chang, Ahn, & Kim, 2017; de Sire et al., 2018; Hu et al., 2019; Passey, 
Bozinovski, Vlahos, Anderson, & Hansen, 2016; Szychlinska et al., 2019; Zhu et 
al., 2017). 
The pleiotropic effects of IL-6 are likely a result from the different effects of 
IL-6 signaling within these various cell populations residing within muscle. 
Particularly IL-6 has different downstream effects in satellite cells versus 
myofibers. Satellite cells are perhaps the most important muscle cell type since 
they are crucial for muscle repair, regeneration, and adaptability to exercise 
(Brack & Rando, 2012; Chang & Rudnicki, 2014; Kuang & Rudnicki, 2008; 
Shamim, Hawley, & Camera, 2018; Zammit, Partridge, & Yablonka-Reuveni, 
2006). Quiescent satellite cells can become activated and reenter the cell cycle 
to differentiate into myoblasts, which can then further differentiate into myotubes 
(in vitro) or myofibers (in vivo) (Konigsberg, 1963; Snow, 1977; Yaffe, 1969). 
Myoblasts isolated from rat, murine and human skeletal muscle have been used 
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to generate stable myogenic clones for cell culture, with the most well-known 
being the rat L6 myoblasts, the murine C2C12 myoblasts, and the human HSkM 
myoblasts (Yaffe & Saxel, 1977). Via a combination of experiments utilizing 
myoblasts in vitro and murine genetic knockout models in vivo, the myogenic 
regulatory factors (MRFs) comprised of Myf5, Myod, Mrf4, Myogenin (Molkentin 
& Olson, 1996; Sabourin & Rudnicki, 2000; Tapscott, 2005) and the family of 
myocyte enhancer-binding factor 2 (Mef2) proteins consisting of Mef2a, 2b, 2c, 
and 2d (Black & Olson, 1998; McKinsey, Zhang, & Olson, 2002) were found to be 
critical transcription factors regulating myogenesis. In satellite cells, transient 
exposure to low levels of IL-6 activates STAT3, which directly interacts with Myod 
(Yang et al., 2009) and is associated with increased satellite cell proliferation (K. 
Wang, Wang, Xiao, Wang, & Wu, 2008) and satellite cell-mediated myofiber 
repair and myofiber hypertrophy (Cantini et al., 1995; Serrano, Baeza-Raja, 
Perdiguero, Jardi, & Munoz-Canoves, 2008; Steyn, Dzobo, Smith, & Myburgh, 
2019; Tierney et al., 2014; Toth et al., 2011). 
Myofiber hypertrophy is regulated in large part by anabolic signaling and 
activation of the insulin receptor substrate 1 (IRS-1)/phosphatidylinositol-3-kinase 
(PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) protein 
synthesis pathway, where mTOR activation is a well-known mechanism of 
protein synthesis (Egerman & Glass, 2014; Laplante & Sabatini, 2013). When 
activation of Akt is decreased or inhibited, Akt can no longer repress the fork 
head box O (FOXO) transcription factors, which have important roles in muscle 
atrophy including activation of the ubiquitin proteasome pathway through 
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expression of skeletal muscle specific ubiquitin ligases, including 
Fbxo32/MAFbx/Atrogin-1 and Trim63/MuRF-1 (Milan et al., 2015; Schiaffino, 
Dyar, Ciciliot, Blaauw, & Sandri, 2013).  
As in satellite cells, IL-6 activates the JAK/STAT signaling pathway in 
mature myotubes and myofibers, where STAT3 is likely the most (Bonetto et al., 
2011) studied of the STAT family of transcription factors (Narsale & Carson, 
2014; Strassmann, Fong, Kenney, & Jacob, 1992). Neutralization of IL-6 
signaling or STAT3 in muscle attenuates muscle atrophy (Bonetto et al., 2012; 
Cramer et al., 2018; Puppa, Gao, Narsale, & Carson, 2014; Silva et al., 2015; 
Tang et al., 2012; Verstovsek et al., 2010; C. Wu et al., 2019). More specifically, 
inhibition of STAT3 in muscle decreased activation of the ubiquitin-proteosome 
pathway (Silva et al., 2015). Furthermore, activation of STAT3 induces 
expression of suppressor of cytokine signaling 3 (SOCS3), the negative regulator 
of IL-6/STAT3 signaling (Carow & Rottenberg, 2014). SOCS3 has binding affinity 
for IRS-1, which results in repressed function of IRS-1 and decreased activation 
of the PI3K/Akt/mTOR protein synthesis pathway (Al-Shanti & Stewart, 2012; 
Yaspelkis, Kvasha, & Figueroa, 2009; L. Zhang et al., 2009; Zolotnik, Figueroa, & 
Yaspelkis, 2012), providing another mechanism of STAT3 mediated muscle 
atrophy. 
Thus, these findings directly implicate the IL-6/STAT3 signaling pathway in 
both muscle protein synthesis and protein degradation. It also suggests that 
targeting IL-6 signaling in specific cell niches within tissues may be more 
effective than neutralizing IL-6 in circulation in the treatment of muscle wasting.  
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1.4 The Effects of IL-6 Signaling in Adipose Tissue 
In addition to muscle, fat is a highly metabolic tissue and a primary source 
of IL-6 during systemic inflammation (Sindhu et al., 2015). The role of fat as an 
energy storage depot via the storage of triacylglycerol is crucial during times of 
nutrient deprivation and intense exercise. However, mechanisms governing 
hydrolysis of triacylglycerol, commonly referred to as lipolysis, can become 
abnormal during pathological conditions, such as observed in diabetes, obesity, 
and cancer. The relationship between IL-6 and adipose tissue has been 
investigated in detail and stoutly implicates IL-6 signaling, particularly adipocyte-
derived IL-6, as a driver of inflammation and lipolysis (M. S. Han et al., 2020).  
 Lipolysis can occur through multiple signaling pathways culminating in the 
activation of the lipolytic enzymes hormone sensitive lipase (HSL) and adipose 
triglyceride lipase (ATGL), concomitantly with the phosphorylation of perilipin. 
Phosphorylation of perilipin causes its dissociation from the lipid droplet surface 
allowing activated HSL and ATGL access to TG stores and the subsequent 
breakdown of TG into fatty acids and glycerol (Zechner et al., 2012). In concert 
with muscle, IL-6 activates STAT3 in fat, which has been linked to increased 
lipolysis (Pendharkar, Singh, & Petrov, 2018; S. Sun et al., 2017) and reduced 
expression of the pro-adipogenic transcription factors proliferator-activated 
receptor gamma (PPARγ) and CCAAT/enhancer-binding protein alpha (C/EBPα) 
in adipocytes (Almuraikhy et al., 2016; Cortez, Carmo, Rogero, Borelli, & Fock, 
2013). Chronic lipolysis increases plasma fatty acids, which profoundly affects 
systemic tissue metabolism. Skeletal muscle is categorically affected by elevated 
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plasma fatty acids, which causes excessive lipid accumulation known as 
myosteatosis. Myosteatosis is associated with insulin resistance and 
dysmetabolism in muscle. Therefore, it is necessary to consider role of IL-6 
mediated lipolysis when investigating muscle wasting and altered metabolism in 
cachexia. 
 
1.5 Muscle Metabolism 
Atrophy and hypertrophy increase the energy demand of muscle since 
both processes rely on the use of adenosine triphosphate (ATP). Muscle can use 
both glucose and fatty acids to generate ATP. The generation of ATP in muscle 
can occur using either aerobic or anaerobic respiration and the amount of ATP 
generated between the two types of respiration differs greatly. Aerobic respiration 
metabolizes glucose into pyruvate via glycolysis and pyruvate is then oxidized by 
the pyruvate dehydrogenase complex (PDH) to form acetyl-CoA, which is used to 
begin the tricarboxylic acid (TCA) cycle generating NADH and FADH2 to fuel the 
electron transport chain (ETC) and generate 36 ATP molecules. In contrast, 
anaerobic respiration generates 2 ATP and 2 NADH molecules during glycolysis 
and NADH then protonates pyruvate to form lactic acid and NAD+, where NAD+ 
is again protonated to NADH during glycolysis to continue anaerobic respiration.  
Muscle metabolism differs among fiber type isoforms. There are numerous 
such isoforms, however the most common in skeletal muscle are Type I, IIa, IIx 
and IIb in rodents and Type I, IIa and IIx in humans (Sciote & Rowlerson, 1998; 
Toniolo et al., 2005). Type I fibers have a slower shortening velocity and 
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predominantly generate ATP through aerobic respiration, while Type II fibers 
have a more rapid shortening velocity and generate ATP through anaerobic 
respiration (Schiaffino & Reggiani, 2011; Sciote & Rowlerson, 1998; Toniolo et 
al., 2005). Fibers can also use a combination of aerobic and anaerobic 
respiration such as observed in the Type IIa and IIx fibers, both of which have 
capacities for aerobic respiration (Schiaffino & Reggiani, 2011; M. Y. Zhang, 
Zhang, & Medler, 2010). Because Type I fibers contract more slowly and usually 
have smaller fiber cross-sectional areas (CSA) compared to Type II fibers, Type I 
fibers generate less force production than the faster and larger Type II fibers 
(Schiaffino & Reggiani, 2011).  
Glucose uptake into myofibers for use in glycolysis requires the presence 
of glucose transporters (GLUT) within the plasma membrane. There are more 
than twelve GLUT transporters and GLUT4 is the most expressed isoform at the 
muscle membrane after insulin stimulation (Navale & Paranjape, 2016). Insulin 
signaling directly regulates glucose uptake in muscle.  Insulin binds the alpha-
subunit on the insulin receptor (IR), which induces autophosphorylation of the IR 
beta-subunit and promotes downstream phosphorylation and activation of insulin 
receptor substrates (IRS) (Eckstein, Weigert, & Lehmann, 2017). IRS-1 is the 
predominant isoform in muscle and activation of IRS-1 leads to downstream 
activation of the PI3K/Akt/mTOR pathway, where Akt phosphorylates and 
activates downstream substrates important for the trafficking of GLUT4 to the 
plasma membrane (Guo et al., 2019). Thus, intact insulin signaling in muscle is 
important for both regulation of muscle hypertrophy and glycolysis.  
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During hypoglycemia and depletion of muscle glycogen stores, muscle 
can use fatty acids as a fuel source (Margolis et al., 2019). Fatty acids can be 
directly taken up by myofibers through fatty acid transporters or generated from 
lipid stores within muscle from TAG hydrolysis (Shang et al., 2019; Turcotte et 
al., 2000). Fatty acid oxidation (FAO) in muscle can occur through various 
mechanisms, but beta-oxidation occurring within the mitochondria is perhaps the 
most common. Beta-oxidation of FA is the breakdown of longer FA into fatty 
acyls containing two carbons (acetate), which is then combined with co-enzyme 
A (CoA) to form acetyl-CoA. Acetyl-CoA can then be used in the TCA cycle, to 
generate intermediates for use in the ETC and generation of ATP as described 
previously. Furthermore, to prioritize FAO, pyruvate entry into the TCA cycle for 
oxidation is slowed or halted by activation of pyruvate dehydrogenase kinase 
(PDK), which inhibits the function of PDH (Harris, Bowker-Kinley, Huang, & Wu, 
2002). In muscle, PDK4 is the predominate isoform and is transcriptionally 
regulated by FOXO1 (Bowker-Kinley, Davis, Wu, Harris, & Popov, 1998; 
Furuyama, Kitayama, Yamashita, & Mori, 2003). This regulation relates impaired 
insulin signaling or reduced glucose availability with decreased activation of Akt 
and subsequent de-repression of FOXO1 and downstream activation of PDK4. 
Thus, creating a link between impaired glucose metabolism and increased 
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1.6 Myosteatosis and Bioactive Lipid Signaling in Muscle 
When presented with chronically high levels of plasma FA, muscle can 
increase FA uptake and oxidation. However, if FA uptake outpaces FAO then 
muscle accumulates triacylglycerol in the form of lipid droplets, which can 
become pathological and known as myosteatosis. Myosteatosis is not a novel 
research question per se; however, our understanding of the specific 
mechanisms and downstream effects of myosteatosis on muscle size and 
metabolism is lacking. Myosteatosis is reported in multiple chronic inflammatory 
diseases and may be a suitable target for restoring muscle size and metabolism 
homeostasis.  
Muscle commonly acquires plasma fatty acids during non-pathological 
conditions like exercise and fasting, which results in acute increases in muscle 
lipid followed shortly by their oxidation and clearance from the muscle (Daemen, 
van Polanen, & Hesselink, 2018; Dotzert et al., 2018). However, during chronic 
inflammation and lipid mobilization from fat stores, lipid accumulation surpasses 
lipid oxidation in muscle and results in synthesis and storage of triacylglycerol 
(TAG) in muscle (Daemen et al., 2018). Myosteatosis negatively impacts muscle 
in a number of ways. First, it alters muscle metabolic homeostasis by increasing 
insulin resistance and reactive oxygen species (ROS) due to increased 
endoplasmic reticulum (ER) and mitochondrial stress (J. Han & Kaufman, 2016; 
Jung et al., 2018; Morales, Bucarey, & Espinosa, 2017; Y. Wang et al., 2019). 
Next, this aberrant metabolism inhibits anabolic pathways such as the 
PI3K/Akt/mTOR pathway while also activating the ubiquitin proteosome pathway, 
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resulting in muscle atrophy (Fukawa et al., 2016; Pellegrinelli et al., 2015; 
Woodworth-Hobbs et al., 2017).  
Myosteatosis-induced insulin resistance largely occurs from activation of 
lipid sensitive signaling molecules as a result of the increased accumulation of 
bioactive lipids. Diacylglycerols (DAG) are among the most characterized 
bioactive lipids. DAGs are commonly synthesized in healthy muscle and are 
essential for plasma membrane formation, signaling pathways and energy 
storage (Massart & Zierath, 2019). DAGs are comprised of two fatty acid chains 
bonded to a glycerol backbone and can be generated at multiple subcellular 
compartments including the ER, Golgi apparatus, lipid droplets and the plasma 
membrane. Generation of DAGs can be both catabolic and anabolic, occurring 
during the hydrolysis of TAG as well as de novo synthesis of TAG using fatty 
acids, acyltransferases and phosphohydrolases. DAGs plays a crucial role in 
inflammatory and metabolic diseases through their interactions with downstream 
signaling mediators, especially the protein kinase C (PKC) family of kinases 
(Massart & Zierath, 2019). 
 PKC activation is important in a variety of biological functions including T-
cell activation (Altman, Isakov, & Baier, 2000; Isakov & Altman, 1987), cell cycle 
and differentiation (Carter et al., 2013; Nitti et al., 2010; Poli et al., 2018; Ye et 
al., 2019), cell survival (Cardoso et al., 2018; L. Liu et al., 2018; J. Zhang et al., 
2018), inflammation (Ali & Sarna, 2002; Xu et al., 2010; J. Yang et al., 2013), and 
metabolism (Greene et al., 2014; Kim et al., 2004; Mayr et al., 2004; Ramzy et 
al., 2006; Tsuru et al., 2002). Activated PKC isozymes, especially DAG sensitive 
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cPKCs and nPKCs, have a well-documented role in inflammation, insulin 
resistance, and alterations in tissue metabolism homeostasis, implicating this 
family of kinases as an important signaling node in myosteatosis-induced muscle 
wasting and dysmetabolism.  
Yasutomi Nishizuka family of serine/threonine kinases within bovine and 
rat brain in 1979(Kishimoto, Kajikawa, Shiota, & Nishizuka, 1983; Takai et al., 
1979) . There are now multiple PKC isozymes categorized into three 
subfamilies, conventional (cPKC) including PKCa, bI, bII and g, novel (nPKC) 
including PKCd, e, h, and q, and atypical (aPKC) including PKCi and z (Lipp & 
Reither, 2011; Marrocco et al., 2019). Each PKC isozyme contains a C-terminal 
catalytic kinase region and a N-terminal regulatory region joined by a middle 
hinge region. Activation of PKC requires three specific phosphorylation events 
within the C-terminus of the kinase. The first phosphorylation event occurs at a 
threonine residue located within the activation loop and is trans-phosphorylated 
by phosphoinositide-dependent protein kinase-1 (Pdk1) causing the kinase to 
become catalytically competent (Dutil, Toker, & Newton, 1998; Y. Liu, Graham, 
Li, Fisher, & Shaw, 2002). Next, two autophosphorylation events occur within the 
C-terminus, one at a threonine residue acting to further stabilize the catalytically 
active kinase (Newton, 1995) and the second at a serine residue, which 
promotes the release of the mature PKC into the cytosol (Newton, 1995). The 
specific positions of the residues to be phosphorylated are isozyme dependent. 
Interestingly, phosphorylated cytosolic PKC maintains a pseudo-substrate in its 
catalytic region preventing it from phosphorylating downstream substrates. 
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Phosphorylated PKC must be trans located to the plasma membrane and 
anchored there by phosphatidylserine for removal of the pseudo-substrate, a 
process that is regulated in cPKCs and nPKCs by the secondary messengers 
calcium (Ca2+) and diacylglycerol (DAG). Translocation regulation in the aPKCs 
remains less understood but likely occurs through interaction with the 
phosphoinositide-3 kinase (PI3K) pathway(Farese, Sajan, & Standaert, 2005) . 
Within the regulatory domain, the cPKC and nPKC subfamilies contain two C1 
domains (C1A and C1B) critical for DAG binding and one C2 domain important 
for Ca2+ binding (Evans, Murray, Leslie, & Falke, 2006; Farah & Sossin, 2012; 
Nalefski & Falke, 1996; Sutton, Davletov, Berghuis, Sudhof, & Sprang, 1995; G. 
Zhang, Kazanietz, Blumberg, & Hurley, 1995). In cPKCs, the C1 domain (DAG 
binding) precedes the C2 domain (Ca2+ binding) making this subfamily sensitive 
to both Ca2+ and DAG. Translocation occurs through the binding of calcium with 
the C2 domain, increasing the affinity of the C2 domain for phosphatidylserine, 
while accumulation of DAG at the plasma membrane binds with the C1 domain 
(Ayo, Radnik, Garoni, Troyer, & Kreisberg, 1991; Huang, 1989). In nPKCs, the 
C1 domain is insensitive to Ca2+ and follows the C2 domain in the structural order 
within the regulatory region. While insensitive to calcium, the C1 domain of 
nPKCs is thought to possess a basal affinity for phosphatidylserine through 
alterations in domain structure (Nalefski & Falke, 1996), making nPKC 
translocation to the plasma membrane only sensitive to DAG (Bell & Burns, 
1991; Konno, Ohno, Akita, Kawasaki, & Suzuki, 1989; Mellor & Parker, 1998; 
Newton, 2001; Nishizuka, 1992; Ron & Kazanietz, 1999). The aPKCs lack a C2 
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domain and contain a DAG insensitive C1 domain, which has an affinity for 
ceramides and downstream products of the PI3K pathway such as 
phosphatidylinositol (3,4,5)-triphosphate promoting its translocation to the plasma 
membrane (Sanchez, De Carcer, Sandoval, Moscat, & Diaz-Meco, 1998). Once 
positioned on the cytosolic side of the plasma membrane, the conformation of the 
activated kinase allows for degradation of the pseudo-substrate and PKC is able 
to phosphorylate downstream targets.  
 
1.7 Pancreatic Ductal Adenocarcinoma-Associated Cachexia and IL-6 
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers 
with a five-year mortality rate of >91% (Siegel, Miller, & Jemal, 2019). Cachexia 
affects over 80% of patients with PDAC and leads to increased morbidity and 
mortality (Hendifar et al., 2018; L. Sun, Quan, & Yu, 2015; von Haehling, Anker, 
& Anker, 2016). Both cancer and cachexia are associated with systemic 
inflammation affecting multiple organ systems (Argiles, Stemmler, Lopez-
Soriano, & Busquets, 2018; Onesti & Guttridge, 2014). While various cytokines, 
chemokines, and growth factors are changed in PDAC, Interleukin-6 (IL-6) 
specifically has been positively correlated with PDAC presence (Holmer, 
Goumas, Waetzig, Rose-John, & Kalthoff, 2014), disease progression (Ramsey 
et al., 2019), mortality (Babic et al., 2018; Suh et al., 2013), and cachexia (Okada 
et al., 1998) (Ebrahimi, Tucker, Li, Abbruzzese, & Kurzrock, 2004) (Martignoni et 
al., 2005). Although circulating IL-6 levels are not always detectable in early 
PDAC nor always correlated with cachexia severity (Ramsey et al., 2019; Talbert 
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et al., 2018), higher tumor staining for IL-6 is associated with PDAC cachexia 
(Martignoni et al., 2005) and induction of monocyte IL-6 is predictive of survival in 
PDAC (Moses, Maingay, Sangster, Fearon, & Ross, 2009), suggesting that the 
serum levels of this short-lived cytokine might not be an inappropriate measure of 
tissue activity. Functional data also support a role for IL-6 in PDAC tumor 
development (Lesina et al., 2011), progression (Y. Zhang et al., 2013), 
metastasis (Razidlo, Burton, & McNiven, 2018), anti-tumor immunity (Flint et al., 
2016), and response to chemotherapy (Long et al., 2017). IL-6 levels are high in 
PDAC models with weight loss (Flint et al., 2016) and IL-6 is also functionally 
linked to cachexia in murine C26 colon adenocarcinoma and other models of 
cancer cachexia (Baltgalvis et al., 2008; Bonetto et al., 2012; Bonetto et al., 
2011; Narsale & Carson, 2014). Moreover, IL-6 is sufficient to induce cachexia in 
mice (Baltgalvis et al., 2009; J. L. Chen et al., 2016; Tsujinaka et al., 1996) as 
well as lipolysis and atrophy in cultured adipocytes (Trujillo et al., 2004) and 
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CHAPTER 2: TUMOR, SKELETAL MUSCLE AND ADIPOSE TISSUE 
CROSSTALK IN PDAC 
 
2.1 Overview 
 Given its various roles in PDAC, lipolysis and muscle wasting, here 
I investigated the effects of IL-6 emanating from PDAC tumor cells on tissue 
crosstalk and cachexia using isolated mouse PDAC cells deleted for IL-6 (KPC 
IL-6KO) in a mouse model of pancreatic cancer cachexia. Furthermore, I used this 
approach to characterize fat and muscle crosstalk via IL-6 signaling and 
myosteatosis in pancreatic cancer cachexia. Specifically, I evaluate the effects of 
tumor cell-derived IL-6 on muscle atrophy in vitro by treating C2C12 myotubes 
with KPC and KPC IL-6KO cell conditioned media and in vivo, using orthotopic 
implantation of KPC and KPC IL-6KO cells. I also report changes to global gene 
expression in skeletal muscle and adipose tissue associated with deletion of 
tumor-derived IL-6 using RNA-sequencing. Furthermore, I determined skeletal 
muscle to be the primary contributor of sIL6R in plasma and adipose tissue as 
the primary contributor of circulating IL-6. I also observed significant 
myosteatosis only in KPC tumor-bearing mice suggesting a potential role for 
tumor IL-6 and dysmetabolism in muscle. Collectively, my results suggest a feed-
forward signaling loop between tumor-derived IL-6, myosteatosis and muscle 
sIL6R trans-signaling with adipose tissue IL-6 production working in concert to 
exacerbate dysmetabolism and atrophy in skeletal muscle in PDAC.  
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2.2 Materials and Methods 
A detailed list of cell lines, mouse strains, equipment and reagents is provided in 
Table 2.1 
 
2.2.1 Immunohistochemistry (IHC) Performed on Human and Mouse Tumors 
Formalin-fixed human pancreatic ductal adenocarcinoma (PDAC) tumor 
arrays were obtained from US Biomax (PA1001a, Rockville, MD, USA) and 
consisted of 100 core samples from 50 patients. Twenty-eight core samples 
consisting of normal pancreas tissue or tumor samples having no reactivity for IL-
6 were excluded. The final sample population was made up of 72 core samples 
and included 21 males and 15 females ranging in age from 40-78 years of age. 
Tumor samples varied in stage from IB (maximum tumor diameter greater than 
four centimeters) to IV (metastases in four or more regional lymphnodes) as 
defined by the 8th edition of AJCC cancer staging manual. Sections were 
deparaffinized with xylenes and rehydrated using deionized water (dH2O). 
Antigen retrieval was performed by incubating the sections in a sodium citrate 
buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) at 95° C for 10 minutes 
and allowing them to cool to room temperature for 30 minutes. Sections were 
washed using dH2O and endogenous peroxidase was quenched using 3% 
hydrogen peroxide (S25360, Thermo Fisher; Waltham, MA, USA). Sections 
incubated with blocking buffer which was comprised of 8% FBS (SH3007103HI, 
Thermo Fisher; Waltham, MA USA) in PBS (21040CV, Corning; Corning, NY, 
USA) for one hour and incubated overnight in a humid chamber at 4° C with an 
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anti-IL-6 monoclonal antibody (mAb) (ab6672, Abcam; Cambridge, MA, USA) 
diluted 1:400 in blocking buffer. Detection and visualization of the anti-IL-6 mAb 
was done using ImmPACT DAB Peroxidase (HRP) Substrate kit from Vector 
Laboratories (SK-4105, Burlingame, CA, USA). Sections were counter stained 
with hematoxylin for one minute, dehydrated and cleared using sequential 
incubations (3 minutes each) of dH2O, 70% ethanol, 95% ethanol, 100% xylenes 
and then cover slips applied.  
 
2.2.2 In Vitro Cell Culture 
C2C12 mouse myoblasts were purchased from ATCC (CRL-1772; Manassas, 
VA, USA). 3T3 fibroblasts were purchased from Zen Bio (SP-LF-1, Zen Bio; 
Research Triangle Park, NC, USA). KPC tumor cells were a gift from Dr. David 
Tuveson, who isolated them from a pancreatic tumor from a male LSL-
KrasG12D: LSL-Trp53R172H:Pdx1-Cre (KPC) mouse on a C57BL/6 background 
(Hingorani et al., 2005) and we used these cells to generate the KPC IL-6KO cells 
(RRID: CVCL_UR56). 
 
2.2.3 C2C12 Mouse Myoblast Cell culture and Differentiation into Myotubes 
Frozen murine C2C12 myoblasts (2 X 106 cells) were thawed in a 37°C water 
bath and then seeded in flasks (130191, Thermo Scientific; Waltham, MA, USA) 
containing 20 mL of growth media (GM), which consisted of DMEM base media 
(10013CV, Corning; Corning, NY, USA), 10% fetal bovine serum (FBS) 
(SH30071.03, GE Healthcare Life Sciences; Pittsburgh, PA, USA) and 0.1% 
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penicillin and streptomycin (15140122, ThermoFisher Scientific, Waltham, MA, 
USA; ) and maintained in a humidified incubator at 37°C with 5% CO2 until 70% 
confluent (~2 days). The GM was aspirated, the cells were washed with PBS and 
adherent cells dislodged using 3 mL of 0.25% trypsin (25053CL, Corning; 
Corning, NY, USA). Cells were then seeded 0.3 X 106 cells per well in 6-well 
plates (140685, Thermo Scientific; Waltham, MA, USA) with growth media (GM) 
and maintained at 37°C with 5% CO2 until 90% confluent. The GM was then 
aspirated, cells were washed with PBS and 2 mL per well of differentiation media 
(DM) consisting of DMEM base media (10013CV, Corning; Corning, NY, USA), 
2% horse serum (26050-088, Life Technologies; Carlsbad, CA, USA) and 0.1% 
penicillin and streptomycin (15140122, Gibco; Dublin, Ireland) was added and 
cells maintained at 37°C with 5% CO2. The DM was replaced every 48 hours and 
C2C12 myoblasts were fully differentiated into myotubes after 5-6 days in DM. 
 
2.2.4 3T3 Fibroblast Cell Culture and Differentiation into 3T3 Adipocytes 
Frozen 3T3 fibroblasts (0.5 X 106) were thawed and seeded in flasks with 
preadipocyte media (PM-1-L1, Zen Bio; Research Triangle Park, NC, USA) at 
37°C with 5% CO2 in a humidified incubator until 70% confluent. Adherent cells 
were then dislodged using 0.25% trypsin and seeded 0.3 X 106 cells per well in 
six well plates with preadipocyte media and placed in the incubator. Cells were 
allowed to become 100% confluent, at which time cells were maintained at 100% 
confluence in preadipocyte media for an additional 48 hours to ensure growth 
arrest, refreshing the preadipocyte media every 48 hours. Cells were then 
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washed with PBS and differentiation media (DM-2-L1, Zen Bio; Research 
Triangle Park, NC, USA) was added to the wells and cells placed back into the 
incubator. Cells were cultured for three days in differentiation media. Cells were 
then washed with PBS and adipocyte maintenance media (AM-1-L1, Zen Bio; 
Research Triangle Park, NC, USA) was added to the wells and cells placed back 
into the incubator. Cells were cultured in maintenance media for ten days 
refreshing the maintenance media every 48 hours. At ten days, fully differentiated 
3T3 adipocytes were produced. 
 
2.2.5 Generation of KPC and KPC IL-6KO Tumor Cell Lines 
Frozen KPC cells were thawed and cultured flasks with GM as described for 
C2C12 myoblasts. When cells reached 70% confluence adherent cells were 
removed using trypsin (per C2C12 methods) and plated 0.3 X 106 cells per well 
in two separate 6-well plates. Once cells were 70% confluent, Lipofectamine 
3000 (L3000008, Invitrogen; Carlsbad, CA, USA) was used to transfect one plate 
of KPC cells with a CRISPR/Cas9 non-targeting pCMV-Cas9-GFP (CRISPR06-
1EA, Sigma Aldrich; St. Louis, MO, USA) as a control. The additional plate was 
transfected with a CRISPR/Cas9 U6-gRNA:CMV-eCas9-2a-tRFP plasmid 
(MM0000468506, Sigma Aldrich; St. Louis, MO, USA) targeting the mIl6 gene. 
Cells were incubated for 48 hours with the lipofectamine and CRISPR plasmids. 
Cells were removed from the wells using trypsin and sorted one GFP-positive cell 
(control) or one RFP-positive cell (IL-6KO) per well into separate 96-well plates 
(167008, Thermo Fisher; Waltham, MA, USA) using fluorescence-activated cell 
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sorting (FACS). One 96-well plate contained cells transfected with the non-
targeting control plasmid and the other plate contained cells transfected with the 
plasmid targeting Il6. Single cell cultures were maintained in GM and expanded 
into colonies over ~4 weeks. Colonies transfected with the plasmid targeting mIl6 
were screened for loss of Il6 mRNA expression using RT-PCR. The selected 
clone with loss of Il6 mRNA expression was designated KPC IL-6KO. Colonies 
transfected with the non-targeting control plasmid were screened using RT-PCR 
for Il6 mRNA expression similar to that of the non-transfected parental cell line 
(KPC-P) and the control clone selected was designated KPC. 
 
2.2.6 Proliferation Assay of KPC Cells 
Comparison of in vitro proliferation between non-transfected KPC cells 
(KPC-P), KPC cells transfected with a null CRISPR/Cas9 plasmid (KPC) and the 
mutant KPC IL-6KO cells was performed using the xCELLigence Real-Time Cell 
Analysis (RTCA) assay (ACEA Biosciences; San Diego, CA). Cells were plated 
in GM at 2,000 cells per well in triplicate in an Eplate 16 (ACEA Biosciences; San 
Diego, CA). Cell growth was measured each hour for 100 hours. 
 
2.2.7 In Vivo Mouse Experiments 
Experiments that included mice were approved by and performed in 
accordance with the Indiana University School of Medicine Institutional Animal 
Care and Use Committee. Seven-week-old male C57BL/6J mice (000664, 
Jackson Laboratory; Bar Harbor, Maine, USA) mice were group-housed in a 
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barrier facility with ad libitum access to autoclaved food (Envigo: Huntingdon, 
Cambridgeshire, United Kingdom), sterile water, maintained on a 12hr light/dark 
cycle and allowed to acclimate to the facility for one week. 
 
2.2.8 Orthotopic Implantation of KPC and KPC IL-6KO Cells into Mice 
Eight-week-old, male C57BL/6J mice were anesthetized using 4% 
isoflurane in an induction chamber within a biosafety cabinet. Mice were 
subcutaneously injected with buprenorphine (4202317005, PAR 
Pharmaceuticals; Chestnut Ridge, NY, USA) at 0.5 mg/kg in 0.1 mL sterile PBS 
prior to surgery and then every 12 hours from the first injection for 48 hours.  
The abdomen was shaved, and mice were placed in lateral recumbency 
with the right side against a heated surgical platform and the left side facing 
upward. From this point forward aseptic technique was maintained. A sterile 
drape was placed over the abdomen and a hole cut in the drape to reveal the 
abdominal skin. The skin was prepped using three alternating scrubs of Betadine 
(6761815117, Purdue Products; Stamford, CT, USA) and 100% isopropanol. An 
incision (~1 cm) was made through both skin and muscle into the left middle 
quadrant of the abdomen directly above the spleen using scissors. The pancreas 
was retracted using ring tip forceps by gripping the spleen (which is loosely 
connected with the pancreas) and retracting both the spleen and pancreas onto 
the sterile drape. The pancreas was injected with 5 x 104 KPC or KPC IL-6KO 
cells in 50µl GM of cells using a 1 mL syringe with a 26G needle (329652, 
Becton, Dickinson and Co.; Franklin Lakes, NJ, USA) over a period of thirty 
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seconds. The spleen and accompanying pancreas were gently laid back into the 
abdominal cavity using the ring tip forceps. The incision was closed by suturing 
the abdominal wall musculature using absorbable 4.0-vicryl suture (33227, Butler 
Schein Animal Health; Dublin, OH, USA) and the skin flap closed using stainless 
steel wound clips (500346, World Precision Instruments; Sarasota, FL, USA).  
 
2.2.9 Euthanasia and Tissue Excision from Animal Models 
All mice were euthanized when any group exhibited average body weight 
loss >10% or total fat mass <5% via EchoMRI. Euthanasia under general 
anesthesia (4% isoflurane) was done by exsanguination via cardiac puncture 
followed by cervical dislocation. Prior to euthanasia, blood was collected in EDTA 
tubes (366643, Becton, Dickinson and Co.; Franklin Lakes, NJ, USA) via cardiac 
puncture after anesthetizing the mice. The plasma was separated using 
centrifugation of the blood at 3,500 rpm at 4°C and stored at -80°C. Immediately 
following euthanasia tissues were excised and weighed. Sections of tissues were 
either placed into 2 mL cryogenic storage vials (82050-208, VWR; Radnor, PA, 
USA) and snap frozen in liquid nitrogen. Additionally, sections of tumor were 
placed into tubes containing 10% neutral buffered formalin (NBF) and sections of 
epididymal fat were placed into tubes containing Bouin's solution 23-005-69, 
Thermo Fisher; Waltham, MA USA) for 24 hours. Fixed tumor and fat tissues 
were washed twice with PBS and transferred to new tubes containing 70% 
ethanol and stored at 4°C.  Sections of the quadriceps muscle were mounted to 
cork discs, keeping the muscle fascicles perpendicular to the disc, by using 
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Tissue plus O.C.T. compound (23-730-571, Thermo Healthcare; Waltham, MA 
USA). The muscle blocks were snap frozen by submerging the mounted muscle 
for 45 seconds in isopentane (2-methylbutane) (03551-4, Fisher Chemical; 
Waltham, MA USA) cooled to -150°C in a bath of liquid nitrogen and then stored 
at -80°C. 
 
2.2.10 RNA Isolation, Library Preparation, Sequencing and Quantitative PCR 
(qPCR) 
RNA was isolated from ~50 mg of snap frozen tissue or from cells cultured 
in 6-well plates via the miRNeasy Mini Kit (217004, Qiagen; Fredrick, MD USA). 
The concentration and quality of total RNA samples was first assessed using 
Agilent 2100 Bioanalyzer. A RIN (RNA Integrity Number) of six or higher was 
required to pass the quality control. Isolated RNA from quadriceps and 
epididymal fat pads was taken from four animals per group (i.e. No tumor, KPC 
tumor and KPC IL-6KO tumor mice) and subjected to next generation sequencing. 
For adipose tissue, 500 nanograms (ng) of RNA per sample were used to 
prepare dual-indexed strand-specific cDNA library using TruSeq Stranded mRNA 
Library Prep Kit (Illumina; San Diego, CA, USA). For skeletal muscle, 100 ng of 
RNA per sample were used to prepare single-indexed strand specific cDNA 
library using TruSeq Nano DNA Library Prep kit.  
 The resulting libraries were assessed for quantity and size distribution 
using a Qubit and Agilent 2100 Bioanalyzer. 200 picomolar pooled RNA libraries 
were utilized per flow cell for clustering amplification on cBot using HiSeq 
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3000/4000 PE Cluster Kit and sequenced with 2×75bp paired-end configuration 
on HiSeq4000 (Illumina; San Diego, CA, USA) using the HiSeq 3000/4000 PE 
SBS Kit.  A Phred quality score (Q score) was used to measure the quality of 
sequencing. More than 95% of the sequencing reads reached Q30 (99.9% base 
call accuracy) for both muscle and adipose tissues. 
The sequencing data were first assessed using FastQC (Babraham 
Bioinformatics, Cambridge, UK) and then all sequenced libraries were mapped to 
the mm10 mouse genome using STAR RNA-seq aligner (Dobin et al., 2013). 
Uniquely mapped sequencing reads were assigned to mm10 UCSC reference 
genome. The data were normalized using the TMM (trimmed mean of M values) 
method. One muscle sample from the No Tumor group was identified as an 
outlier and removed from further analyses. Differential expression analysis was 
performed using edgeR (McCarthy, Chen, & Smyth, 2012; Robinson, McCarthy, 
& Smyth, 2010) and the false discovery rate (FDR) was computed from p-values 
using the Benjamini-Hochberg procedure. Differentially expressed genes were 
determined as having a fold change of ≥1.5 and an FDR of ≤ 0.05. Ingenuity 
Pathway Analysis (Qiagen; Fredrick, MD USA) was used for secondary analysis 
of RNA sequencing results. Data are deposited into GEO Datasets under series 
record GSE123310. 
For qPCR analyses, 100 ng of isolated RNA was reverse transcribed into 
cDNA using the VERSO cDNA Synthesis Kit (AB1453B, Thermo Fisher; 
Waltham, MA USA). Taqman Universal Master Mix II (4440038, Thermo Fisher; 
Waltham, MA, USA) and gene specific Taqman probes (see Table 2.1) were 
	 	 27 
used to measure gene expression using cDNA in Light Cycler 480 96-well plates 
(04729692001, Roche; Indianapolis, IN, USA) on a Light Cycler 96 (Roche; 
Indianapolis, IN USA). For each sample, TATA binding protein (Tbp) gene 
expression was used to normalize the expression of the target gene. Each well 
contained one PCR reaction and reactions for each sample of cDNA were 
performed in triplicate for both target and control genes. Results from qPCR 
analyses were analyzed using the 2-ΔΔCT method and reported as fold change.  
 
2.2.11 Western Blotting 
 Tissue protein lysates were made by homogenizing snap frozen tissue in 
ice cold RIPA buffer (Harlow & Lane, 2006) using a Polytron PT 10/35 
homogenizer with PCU 11 controller (Kinematica; Luzern, Switzerland). Protein 
lysate concentration was measured using the PierceTM BCA Protein Assay Kit 
(PI23228, Thermo Scientific; Waltham, MA USA). Protein lysate was then added 
1:1 to 2X sample buffer (125 mM Tris; pH 6.8, 4% (w/v) SDS, 20% glycerol, 100 
mM DTT, 0.02% (w/v) bromophenol blue) and heated at 95°C for five minutes. 
Proteins were then separated via SDS-PAGE by loading 30 µg of protein from 
each sample into wells on a 4-15% CriterionTM TGXTM gel (5671084, Bio-Rad; 
Hercules, CA, USA) in running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) 
at 140 volts for one hour using a Power Pac HC (Bio-Rad; Hercules, CA, USA). 
The proteins were transferred to 0.2μm nitrocellulose membranes (1620233, Bio-
Rad; Hercules, CA, USA) in ice-cold transfer buffer (25 mM Tris, 192 mM glycine, 
20% (v/v) methanol, pH 8.3) at 100 volts for thirty minutes. Membranes were 
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blocked using Sea Block (37527, Thermo Scientific; Waltham, MA USA) for one 
hour at room temperature on a shaker table. Proteins were detected using 
antigen specific primary antibodies (see Table 2.1) diluted in Sea block with 0.1% 
Tween 20 (BP337-500, Fisher Scientific; Waltham, MA USA) and incubated with 
the membranes overnight at 4°C. Membranes were then washed twice with PBS 
and primary antibodies were visualized using florescent DyLightTM secondary 
antibodies (Cell Signaling; Danvers, MA, USA) with specificity against the 
primary antibodies and imaged on an Odyssey CLx (LiCor; Lincoln, NE, USA). 
The quantification of target proteins was done by normalizing target protein 
expression to the loading control protein expression (α tubulin for muscle, β-actin 
for adipose tissue) specific to each membrane using Image Studio version 4.0 
(LiCor; Lincoln, NE, USA). Normalized protein expression was then presented as 
fold-change versus no tumor bearing mice. 
 
2.2.12 Muscle Histology 
For Oil Red O (ORO) staining, succinate dehydrogenase (SDH) reaction 
and IF performed on muscle, snap frozen mounted muscle blocks were serial 
sectioned (10 μm thickness) at -20°C on a Leica CM1860 cryostat (Buffalo 
Grove, IL, USA) and muscle cross-sections mounted to Superfrost Plus 
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2.2.13 Oil Red O Staining 
ORO staining solution was prepared by dissolving 0.7 g of ORO (00625-
25G, Sigma Aldrich; St. Louis, MO, USA) with 100 mL of 100% propylene glycol 
(398039, Sigma Aldrich; St. Louis, MO, USA) for five minutes at 100°C. The ORO 
staining was then maintained at 60°C until needed. Muscle cross-sections were 
post fixed in 10% NBF for 10 minutes at room temperature. Sections were 
washed for 15 minutes in running tap water, and then submerged in two separate 
bathes of 100% propylene glycol for five minutes each. Sections were then 
incubated in ORO staining solution for ten minutes with gentle shaking, washed 
in 85% propylene glycol for three minutes and rinsed using distilled water for 
three minutes. Sections were counterstained with Harris Modified Hematoxylin 
(SH26-500D, Fisher Chemical; Waltham, MA USA), rinsed with running tap water 
for ten minutes, rinsed with distilled water for three minutes and then counter 
slips were mounted using Prolong Gold Antifade Mountant (P36934, Life 
Technologies; Carlsbad, CA, USA). 
 
2.2.14 SDH Reaction 
Glass Coplin jars were prewarmed to 37°C in an incubator prior to 
beginning the reaction. Succinic acid solution was made by adding 0.4 g of 
succinic acid (6106-21-4, Acros Organics; New Jersey, USA), 0.04 g nitroblue 
tetrazolium (N8129, Sigma Aldrich; St. Louis, MO, USA) and 0.001 g of 
phenazine methosulfate (P9625, Sigma Aldrich; St. Louis, MO, USA) to 40 mL of 
0.1M Tris buffer and pH equilibrated to 7.01. The succinic acid solution was 
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warmed to 37°C and the muscle sections were submerged in the solution for 30 
minutes maintaining the temperature at 37°C in an incubator. Sections were then 
washed using a series of 30%, 60%, 90%, 60%, 30% acetone (A18-1, Fisher 
Chemical; Waltham, MA USA) solutions for 5 seconds each and rinsed in distilled 
water. Coverslips were applied using Prolong Gold Antifade mounting media. 
 
2.2.15 Measurement of C2C12 Myotube Diameter and Quadriceps Muscle Fiber 
Cross-sectional Area (CSA) 
Fully differentiated myotubes were washed with PBS and fixed by 
incubation with ice-cold acetone and methanol (A412-4, Fisher Chemical; 
Waltham, MA USA) (1:1) at -20°C for 15 minutes. Myotubes were washed with 
PBS twice and blocked using blocking buffer (8% FBS in PBS) at room 
temperature for one hour. Myotubes were then incubated with an anti-myosin 
primary mAb (MF 20, DSHB; Iowa City, IA, USA) at a dilution of 1:50 in blocking 
buffer overnight at 4° C in a humid chamber. Myotubes were washed with PBS 
and incubated with a florescent secondary antibody (A-11029, Thermo Fisher; 
Waltham, MA USA) for one hour at room temperature in a humid chamber. 
Myotubes were washed with PBS, imaged and myotube diameter measured 
using Image J analysis. 
IF was performed on frozen muscle cross-sections that were post-fixed in 
pre-cooled acetone (-20°C) for ten minutes and placed at room temperature for 
30 minutes. Sections were washed twice in PBS and then blocked by incubating 
the sections with blocking buffer for one hour at room temperature. The sections 
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were washed with PBS and incubated with the primary antibodies against IL6R 
and CD31 (see Table 2.1 for antibody information) diluted in blocking buffer 
overnight at 4°C in a humid chamber. Sections were washed and the secondary 
antibody applied (see Table 2.1 for secondary antibody details) at a dilution of 
1:1000 in blocking buffer for one hour at room temperature. Sections were 
washed and incubated with DAPI (268298, EMD Millipore; Burlington, MA, USA) 
for 1 minute to visualize nuclei. Sections were washed and cover slips applied 
using Prolong Gold Antifade mounting media. 
To measure muscle fiber CSA using IF, frozen sections of mouse 
quadriceps muscles were fixed and blocked as described previously and 
incubated with an anti-dystrophin primary antibody (MANDRA11, DSHB; Iowa 
City, IA, USA) and detection of the primary antibody was done using a goat anti-
mouse AlexaFluor 594 florescent secondary antibody (A-11032, Thermo Fisher; 
Waltham, MA, USA). Muscle fiber CSA was measured from images taken of the 
IF dystrophin sections using an ImageJ macro obtained from the Lieber 
laboratory (Mehlem, Hagberg, Muhl, Eriksson, & Falkevall, 2013; Minamoto et 
al., 2007). 
 
2.2.16 Mouse Tumor and Adipose Tissue IHC 
Tumors were excised from mice and immediately fixed in 10% neutral 
buffered formalin (NBF) for 48 hours. Tumors were then washed in PBS and 
stored in 70% ethanol at 4° C until analysis. Tumors were paraffin embedded and 
cross-sections were cut at 5 μm and mounted to microscope slides. 
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Deparaffinization, antigen retrieval, endogenous peroxidase neutralization and 
blocking were performed as previously described for human tumors. After 
blocking, tumors were incubated with an anti-IL-6 mAb (ab7737, Abcam; 
Cambridge, MA, USA) at 1:50 dilution in blocking buffer at 4° C overnight in a 
humid chamber. Detection of the primary mAb, counter staining, clearing and 
cover slip application were performed as described for the human tumors. 
Fixed adipose tissue was washed in PBS and stored in 70% ethanol at 4° 
C. Fixed adipose tissue was then paraffin embedded and sectioned at 5 µm and 
mounted to microscope slides. Deparaffinization, antigen retrieval, endogenous 
peroxidase neutralization and blocking were performed as previously described 
for human tumors. Sections were then incubated with an anti-IL-6 mAb (ab7737, 
Abcam; Cambridge, MA, USA) diluted 1:50 in blocking buffer or an anti-F4/80 
(NB600-404, Novus Biologicals; Centennial, CO, USA) diluted 1:250 in blocking 
buffer overnight at 4° C in a humid chamber. Detection of the primary mAb, 
counter staining, clearing and cover slip application were performed as described 
for the human tumors. 
  
2.2.17 Plasma Analysis of IL-6, IL6R, Glycerol, and Fatty Acids 
 Mouse plasma obtained from cardiac puncture (see section 2.2.9) was 
measured for IL-6 and IL6R protein levels via enzyme-linked immunosorbent 
assay (ELISA) mouse Quantikine kits (MR600 & M6000B, R&D Systems;    
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Minneapolis, MN USA). Plasma glycerol and FAs were measured using Glycerol 
and FA Quantitation Kits (MAK117 & MAK044, Sigma Aldrich; St. Louis, MO 
USA).  
 
2.2.18 Treatment of C2C12 Myotubes and 3T3 Adipocytes with KPC Conditioned 
Media (CM) and Measurement of Il6 and Il6ra mRNA 
C2C12 myoblasts and 3T3 fibroblasts were cultured separately in six well 
plates and differentiated into myotubes and adipocytes, respectively (see 
sections 2.2.2-2.2.4). KPC cells were cultured in GM in flasks until becoming 
100% confluent. At that time, the GM was refreshed and 100% confluent KPC 
cells were maintained for an additional 24 hours. After 24 hours, the CM was 
collected, centrifuged at 3,500 rpm to pellet unwanted cellular debris and the 
supernatant collected. Myotubes and adipocytes were treated in triplicate with 
either 30% GM (control) or 30% KPC CM per well. The treatment media was 
aspirated, cells were washed and myotubes RNA was isolated at 12 hours, 24 
hours and 96 hours after treatment. 3T3 adipocyte RNA was isolated at one hour 
and three hours post-treatment in the same method used for the myotubes. 
Myotube and adipocyte expression of Il6 and Il6r mRNA at each timepoint was 
measured via qPCR using probes for Il6 (Mm00446190, Applied Biosciences; 
Beverly Hills, CA, USA) and Il6r (Mm01211444, Applied Biosciences; Beverly 
Hills, CA, USA). 
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2.2.19 Treatment of Myotubes with IL-6, IL6R and Neutralizing Antibodies 
 C2C12 myoblasts were differentiated into myotubes in six well plates. 
Fully differentiated myotubes were then treated in triplicate with either DF media 
(control), recombinant mouse IL-6 (300 pg/mL) protein (406-ML-005, R&D 
Systems; Minneapolis, MN USA), recombinant mouse IL6R (25 ng/mL) (P9767-
5G, Sigma Aldrich; St. Louis, MO, USA), the combination of IL-6 (300 pg/mL) and 
IL6R (25 ng/mL) (1830-SR-025, R&D Systems; Minneapolis, MN, USA) or IL-6 
(300 pg/mL) in the presence of IL-6 neutralizing antibody (2 mg/mL) (14-7061-85, 
Thermo Fisher; Waltham, MA, USA) for 48 hours. After 48 hours of treatment, 
myotubes were washed with PBS and fixed using ice-cold acetone/methanol 
(1:1) for fifteen minutes at -20° C. Myotubes were then visualized with IF using an 
anti-myosin antibody (see section 2.2.1) and myotube diameter measured with 
Image J. 
 
2.2.20 Statistical Analyses 
The Student t-test was used for the comparison of means between two 
datasets while one-way ANOVA with the Tukey’s post-hoc test was used for 
comparison of the means between three or more datasets. The differences 
between group means was considered statistically different when P<0.05. Data 
are presented as mean ± SEM. All statistical analyses were performed using 
Graph Pad Prism version 7.0 (San Diego, CA, USA). 
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  Table 2.1 An all-inclusive list of reagents and equipment used. 
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 Table 2.1 An all-inclusive list of reagents and equipment used. (Continued) 
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2.3 Results 
2.3.1 Human PDAC Tumor Cells are Heterogeneous for IL-6 Expression  
Immunohistochemistry on human PDAC tumors obtained at surgery 
revealed stromal IL-6 staining in all tumors tested (Figure 2.1 A) as previously 
reported (Mace et al., 2018). However, IL-6 staining in tumor epithelial cells was 
also observed. Of 72 tumor samples, 32 demonstrated weak intensity IL-6 
staining (Figure 2.1 A, top and 2.1 B, left) and 40 samples strong intensity 
staining (Figure 2.1 A, bottom and 2.1 B, right). Expression profiling of human 
PDAC cell lines also confirmed a range of IL6 expression from high (PSN-1, 
Panc03.27, PANC-1) to low (MIA PaCA, AsPC-1, HuPT4) (Figure 2.2). The 
importance of tumor cell-derived IL-6 was further investigated using human 
tumors in a murine xenograft model. Mice implanted with human PDAC tumors 
had a negative correlation when comparing murine IL-6 expression in plasma 
and survival (Figure 2.1 C), loss of quadriceps mass and survival (Figure 2.1 D), 
and a positive correlation between loss of quadriceps mass and plasma IL-6 
(Figure 2.1 E). These results indicate that PDAC epithelial cells are a source of 
IL-6 in the tumor micro- and macro environment and significantly contribute to 
cachexia and survival. 
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Figure 2.1. IL-6 protein expression is heterogeneous in human PDAC 
tumors and is associated with increased mortality and muscle wasting. 
Human PDAC tumors obtained were reacted for IL-6 immunohistochemistry 
(IHC). Tumor sections were classified as having either high or low expression of 
IL-6 specifically in tumor epithelial cells (arrows) (A). Of the 72 tumors, 40 had 
low tumor-cell IL-6 expression and 32 had high tumor-cell IL-6 expression. 
Images using increased magnification to show PDAC tumor cell IL-6 expression 
(B). Xenograft implantation of human tumors into mice showed correlations 
between human IL-6 and mortality (C), muscle loss and mortality (D), and human 
IL-6 and muscle loss (E). Scale bar = 40 μm.
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Figure 2.2. Expression of IL6 RNA in human pancreatic cancer cell lines. 
Expression levels of IL6 mRNA across multiple human pancreatic cancer cell 
lines from Illumina BaseSpace Correlation Engine illustrating heterogeneity in IL6 
expression. 
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2.3.2 PDAC-induced Cachexia and Mortality are Significantly Improved by 
Deletion of IL-6 from Tumor Cells 
To evaluate the effects of tumor cell-derived IL-6 in PDAC cachexia I used 
CRISPR/Cas9 to edit the Il6 gene in a cell line isolated from an autochthonic 
tumor arising in a C57BL/6 male KPC mouse. A similarly transfected clone not 
exposed to gRNAs was used as a control (KPC). Il6 mRNA was detected in the 
parental KPC cell line (KPC-P) and the control KPC line, but not in the KPC-IL6KO 
line (Figure 2.3 A); loss of expression was due to an insertional mutation (Figure 
2.4).  Both control and knockout lines exhibited similar growth characteristics in 
vitro (Figure 2.3 B), indicating that autocrine IL-6 was not required for 
proliferation.  
Deleting IL-6 also abolished muscle-wasting activity associated with KPC 
tumor cell conditioned media. Muscle growth and wasting is often modeled by 
manipulation or treatment of myotubes differentiated from C2C12 myoblasts 
(Figure 2.3 C). IL-6 itself induces atrophy of C2C12 myotubes via a STAT3-
dependent mechanism (Bonetto et al., 2012).  Here, conditioned media from 
KPC cells induced STAT3 phosphorylation (Figure 2.3 D). Myotubes were 
visualized using immunofluorescence for MHC (Figure 2.3 E) and myotube 
diameter was measured resulting in a 25% reduction of myotube diameter in 
those treated with KPC media (Figure 2.3 F). An increase in STAT3 
phosphorylation and a reduction in myotube diameter were absent in KPC-
IL6KOCM treated myotube. To determine if the deletion of IL-6 from KPC IL-6KO 
CM attenuating myotube atrophy, IL-6 was added back to KPC IL-6KO CM media 
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as well as neutralized in KPC CM and KPC IL-6KO + IL-6 CM. Myotubes were 
again visualized using immunofluorescence for MHC (Figure 2.3 G) and 
diameters measured. The addition of IL-6 (300 pg/mL) to KPC IL-6KO CM induced 
myotube atrophy (Figure 2.3 H), while the addition of IL-6 neutralizing antibody (2 
mg/mL) to KPC CM and KPC IL-6KO + IL-6 CM was sufficient to attenuate 
myotube atrophy (Figure 2.3 H). Next, the effects of deleting tumor cell-derived 
IL-6 in vivo were investigated. Orthotopic tumors from mice bearing KPC or KPC 
IL-6KO tumors were reacted for IL-6 expression and positive IL-6 expression in 
KPC cells (Figure 2.3 I, left) and negative IL-6 expression in KPC IL-6KO tumor 
cells (Figure 2.3 I, right) was confirmed. Finally, the deletion of tumor cell-derived 
IL-6 increased the survival of KPC IL-6KO tumor mice compared to KPC tumor 
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Figure 2.3. Deletion of IL-6 from KPC cells prevented muscle wasting in 
vitro and increased survival in mice. Targeted mutagenesis of the Il6 gene 
was performed and Il6 mRNA expression in a transfection control clone (KPC) 
and an Il6 ablated clone (KPC IL-6KO) were compared to non-transfected KPC 
parental cells (KPC-P) and selected for use in downstream experiments (A). The 
parental cell line (KPC-P) was used as a positive control for selection of clones 
(A). To determine if deletion of IL-6 affected tumor cell growth a proliferation 
assay was performed comparing the clones (B). Myoblasts were differentiated 
into myotubes and treated with 30% CM from clones to measure effects on 
myotube atrophy and STAT3 activation (C). Western blotting using myotube 
protein lysates were performed to measure STAT3 phosphorylation (D). 
Myotubes were visualized using florescent immunocytochemistry with an anti-
myosin heavy chain antibody (E) and myotube atrophy measured (F). To verify 
atrophy was due to IL-6, myotubes were treated with KPC IL-6KO CM plus 
recombinant IL-6 with and without the presence of an anti-IL-6 neutralizing 
antibody and the anti-IL-6 neutralizing antibody was also used to treat the KPC 
CM; myotubes were visualized with MHC IF and atrophy measured (G and H). 
KPC tumor cells were orthotopically implanted into mice, tumors were excised, 
sectioned and reacted with anti-IL-6 IHC to verify tumor cell IL-6 deletion (I). 
Survival was measured in mice orthotopically implanted with KPC and KPC IL-
6KO tumor cells (J). Scale bar = 20 μm; Error bars are standard deviation and 
significant differences are shown in the charts. 
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Figure 2.4. Characterization of KPC-IL-6
KO
 cells. DNA sequencing was 
performed at the CRISPR/Cas9 target site (green line) within the murine Il6 gene 
showing an insertion mutation of 45 nucleotides (red line) into the KPC IL-6KO 
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2.3.3 Muscle Wasting is Spared in KPC IL-6KO Tumor-bearing Mice 
 Apart from the survival study, two separate cohorts were analyzed for 
effects on cachexia, euthanizing mice when one group reached specified 
humane endpoints. Cachexia was prominent in the KPC group, with 11% to 26% 
wasting of limb muscles and heart (Figure 2.5 A), with significant loss of body 
weight (Figure 2.6 A) and loss of carcass mass (Figure 2.6 B). In contrast, 
muscle weights in the KPC-IL6KO group were unchanged versus tumor-free 
control mice (Figure 2.5 A) with no change in body weight or carcass mass 
(Figure 2.6 A and 2.6 B). KPC tumor-bearing mice also had wasting of the liver 
(Figure 2.6 C) and increased splenomegaly versus KPC IL-6KO tumor-bearing 
mice (Figure 2.6 D), although KPC IL-6KO tumor-bearing mice had splenomegaly 
when compared to tumor-free mice (Figure 2.6 D). This degree of wasting would 
be considered severe cachexia.   
The quadriceps muscles were sectioned, and individual muscle fibers 
were visualized using immunofluorescence for dystrophin (Figure 2.5 B). Muscle 
from mice with KPC-IL6KO tumors showed normal dystrophin expression, not the 
reduced expression described in murine cachexia (Acharyya et al., 2005; 
Stephens et al., 2015) and observed in mice with KPC tumors (Figure 2.5 B). 
Mice with KPC-IL6KO tumors were also spared the myofiber atrophy observed in 
quadriceps of mice with control KPC tumors (Figure 2.5 C and 2.5 D). Mice 
bearing the KPC tumor had larger tumor mass than mice with KPC IL-6KO tumors 
(Figure 2.5 E). Therefore, to investigate if tumor size was affecting muscle loss, a 
regression analysis was performed comparing tumor mass versus normalized 
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muscle mass. There were no correlations between tumor mass and quadriceps 
mass (Figure 2.5 F) and tumor mass and heart mass (Figure 2.5 G). Tumor mass 
was also compared to the remaining skeletal muscles (Figure 2.6 E and 2.6 F) 
and epididymal fat pad mass (Figure 2.6 G) with no correlations observed. To 
determine if deletion of IL-6 was playing a role in tumor grade and subsequently 
affecting the severity of cachexia, tumors were blindly scored in two independent 
evaluations. There was no difference in tumor grade between KPC and KPC IL-
6KO tumor-bearing mice (Figure 2.6 H). Collectively, these results are consistent 
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Figure 2.5. Deletion of tumor cell IL-6 attenuates muscle wasting. Mice were 
euthanized 17 days after injection due to severe cachexia in the KPC group and 
reaching humane endpoints. Skeletal muscles and the heart were excised at 
euthanasia and weighed and normalized to initial body weight (IBW) (A). 
Evaluation of muscle fiber CSA was done using sections from excised 
quadriceps muscles reacted for dystrophin expression (D) and mean fiber CSA 
measured (B). Cumulative fiber CSA values were organized based on percent 
distribution of fiber CSA and plotted to observe shifts in distribution (C). KPC IL-
6KO excised tumor mass was smaller than KPC tumor mass (E) thus, tumor mass 
was compared with muscle mass to determine if any correlation ns were present 
(F and G).  Scale bar = 50 μm; Error bars are standard   deviation and significant 
differences shown in charts. 
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Figure 2.6. Deletion of tumor cell-derived IL-6 is associated with reduced 
weight loss, carcass and liver wasting, and splenomegaly in mice with 
PDAC. Tumor free final body weight was measured at euthanasia (A) and tissue 
weights for the carcass (B), liver (C) and spleen (D) were also recorded. No 
correlation was observed between tumor mass and gastrocnemius (E), tibialis 
(F), and epididymal fat pad (G) masses. Sections of excised KPC and KPC IL-
6KO tumors were stained with H&E and blindly scored by two separate 
pathologists to determine any differences in tumor grade (H). Error bars are 
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2.3.4 Tumor Cell Deletion of IL6 Reduces Muscle Atrophy Pathway Activation 
Muscle of mice with KPC-IL6KO tumors also demonstrated reduced 
activation of atrophy pathways, including those involved in ubiquitin-proteasome 
mediated proteolysis, autophagy, translation repression, and mitochondrial 
function. Quadriceps muscles from mice with KPC tumors demonstrated 
increased total protein ubiquitination, as commonly observed in conditions of 
muscle catabolism, while total protein ubiquitination in mice with KPC IL-6KO 
tumors was no different from controls (Figures 2.7 A and 2.7 B). Corroboratively, 
RNA levels for the atrophy-associated skeletal muscle E3 ubiquitin ligases 
Fbxo32/Atrogin-1/MAFbx and Trim63/Murf1, were only increased in KPC and not 
KPC-IL6KO muscles (Figure 2.7 B, right). Autophagy and endoplasmic reticulum 
(ER) stress are also triggered in muscle atrophy marked by LC3B-II and Beclin-1, 
proteins with important roles in autophagosome formation (Sandri, 2016) and 
Atf4, which is increased by ER stress and the unfolded protein response 
(Bohnert et al., 2016). LC3B-II and ATF4 protein were increased in the muscle of 
KPC but not KPC IL-6KO tumor-bearing mice (Figure 2.7 C and 2.7 D). While 
Beclin-1 was unchanged in muscle of mice with KPC tumors, it was actually 
decreased in muscle of mice with KPC IL-6KO tumors (Figure 2.7 B and 2.7 D). 
Effects of these KPC tumors on protein synthesis markers in quadriceps were 
subtle, with no significant change in anabolic pAKT/AKT and p-mTOR/mTOR 
(Figure 2.7 E and 2.7 F). A significant decrease in p-4EBP1 in KPC muscle was 
suggestive of de-repression of translation (Figure 2.7 E and 2.7 F). There was no 
difference across groups in the master regulators of mitochondrial biogenesis, 
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PGC1A and PGC1B (Figure 2.7 G and 2.7 H). While there was no difference in 
the mitochondrial uncoupling protein UCP2, an increase in UCP3 was observed 
in mice with KPC tumors, but not in those with KPC-IL6KO tumors (Figure 2.7 G 
and 2.7 H). These results indicated that deletion of IL-6 from tumor cells largely 
abolished activation of muscle wasting pathways, especially those involved in the 
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Figure 2.7. Measurement of protein expression for common molecular 
pathways associated with muscle wasting. Western blotting results evaluating 
muscle proteins involved in ubiquitination (A and B), autophagy (C and D), 
anabolism (E and F) and mitochondria biogenesis and metabolism (G and H) 
from protein lysates made from quadriceps harvested at euthanasia. Analysis of 
qPCR results for mRNA expression of E3 ubiquitin ligases Atrogin-1 and Murf1 in 
quadriceps was also performed (B, right). Error bars are standard deviation and 
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2.3.5 KPC but not KPC IL-6KO Tumors Induced Inflammation, Lipid Accumulation 
and Oxidative Stress in Skeletal Muscle  
RNA sequencing revealed 3480 up-regulated and 3793 down-regulated 
genes [fold change  ³ ½1.5½; false discovery rate (FDR) of 0.05] in the muscle of 
KPC tumor mice, while only 24 up-regulated and 69 down-regulated genes were 
found in the muscle of mice with KPC-IL-6KO tumors (Figure 2.8 A). Pathway 
analysis implicated a number of affected pathways in muscle including 
adipogenesis, oxidative stress, inflammation, fatty acid oxidation (all generally 
increased) and glycolysis, which was decreased (Figure 2.8 B-F). These were 
largely unchanged in mice with KPC-IL-6KO tumors, save fatty acid oxidation, 
which was decreased relative to controls (Figure 2.8 E). Consistent with the 
pathway analysis, Oil Red O staining demonstrated intramyocellular lipid 
accumulation (myosteatosis) in quadriceps of KPC tumor-bearing mice, but not in 
KPC-IL-6KO tumor-bearing or control mice (Figure 2.8 G, top and 2.8 H, left). 
Succinate dehydrogenase (SDH) histochemistry, an indicator of mitochondrial 
respiration and localization, revealed aberrant localization and decreased 
respiratory capacity in the muscle of KPC tumor mice and to some degree in 
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Figure 2.8.  Deletion of IL-6 from KPC cells reduces activation of key 
cachexia pathways in muscle. Isolated RNA from the quadriceps of no tumor, 
KPC tumor and KPC IL-6KO tumor mice was sequenced and differentially 
regulated genes (fold-change ≥ 1.5 and FDR ≤ 0.05) were compared across 
groups (A). Ingenuity Pathway Analysis (IPA) using quadriceps RNA sequencing 
data identified various altered pathways and their associated genes (shown in 
heat map format) that have roles in muscle wasting including adipogenesis (B), 
Oxidative Stress (C), Inflammation (D), Fatty Acid (FA) Oxidation (E) and 
Glycolysis (F); the scale bar illustrates increased (Red) and decreased (Blue) 
gene expression for the heat maps. Measurements of muscle lipids using Oil Red 
O staining (G and H) and succinate dehydrogenase activity as a marker for 
mitochondria oxidative capacity (G and I) were performed on quadriceps muscle 
cross-sections; scale bar = 50 μm, arrows indicate fibers with increased lipid 
accumulation and aberrant SDH reactivity. Error bars are standard deviation and 
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2.3.6 Adipose Tissue is Not Preserved by Tumor-cell Deletion of IL-6 
Because IL-6 has been shown to promote lipolysis, we evaluated tumor 
effects on adipose tissue wasting. Both KPC and KPC-IL-6KO tumor mice had 
wasting of the epididymal fat pad versus no tumor mice, although fat wasting in 
KPC-IL-6KO tumor mice was significantly attenuated (Figure 2.9 A). Consistent 
with this lesser fat wasting, plasma fatty acids and glycerol were increased only 
in the KPC tumor mice (Figure 2.9 B and 2.9 C). RNAseq of adipose tissue 
demonstrated a similar intermediate phenotype, with 268 up-regulated and 145 
down-regulated genes in fat pads of mice with KPC tumors, and 209 up-
regulated and 0 down-regulated genes in the KPC-IL-6KO group (fold change  ³ 
½1.5½; FDR 0.05) (Figure 2.9 D). Granulocyte adhesion/diapedesis, LXR/RXR 
activation, acute phase signaling, and IL-6 signaling were among the top altered 
pathways associated with cachexia in adipose tissue (Figure 2.9 E-H), with 
activated genes similar across both tumor conditions. These results suggest that 
adipose tissue is more sensitive to tumor-produced factors as well as lower 
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Figure 2.9. Deletion of IL-6 from KPC cells reduces fat wasting but did not 
hinder change in gene expression versus KPC tumor mice. Epididymal fat 
pad mass was measured at euthanasia and normalized to initial body weight 
(IBW) (A). Characterization of lipolysis using measurements of plasma glycerol 
(B) and fatty acids (C) normalized to epididymal fat pad mass from mice. Isolated 
RNA from the epididymal fat pads was sequenced and differentially regulated 
genes (compared to no tumor group, fold-change ≥ 1.5 and FDR ≤ 0.05) were 
compared across groups (D). Ingenuity Pathway Analysis (IPA) using epididymal 
fat pad RNA sequencing data identified various altered pathways and their 
associated genes (shown in heat map format) that have roles in inflammation 
and lipolysis including Granulocyte Adhesion/Diapedesis (E), LXR/RXR 
Activation (F), Acute Phase Signaling (G) and IL-6 Signaling (H); the scale bar 
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2.3.7 IL-6 Pathway Proteins are Differentially Expressed in Fat Versus Muscle of 
Mice with PDAC, Implicating IL6R Trans-signaling from Muscle to Fat. 
Given the differential sensitivity of muscle and fat to tumor-derived IL-6, 
we sought to investigate tissue crosstalk in PDAC cachexia. As expected, 
implanted KPC tumor cells and host stromal cells expressed IL-6, while KPC-
IL6KO tumors showed expression only in stroma (Figure 2.3 I). Plasma levels of 
IL-6 were correspondingly increased, with a significant increase (~150-fold) in 
KPC tumor mice over baseline levels, while mice with KPC-IL6KO tumors showed 
roughly half that increase, and the difference were not significantly different from 
normal controls (Figure 2.10 A). Plasma soluble IL-6 receptor (sIL6R), which is 
largely produced by shedding of a 55 kDa fragment from the membrane-bound 
IL6R into the circulation, was also significantly increased in KPC tumor mice 
(~25-fold) over controls; plasma sIL6R levels in KPC-IL6KO mice were not 
different from controls (Figure 2.10 B). 
To identify the sources of IL-6 and sIL6R, I measured mRNA in muscle, 
fat, liver and tumor and protein in the quadriceps muscle and the epididymal fat 
pads via western blotting. The results indicate that both muscle and fat express 
IL-6 in PDAC cachexia, and further that muscle is a source of circulating sIL6R, 
enabling trans-signaling of IL-6 in adipose tissue. Specifically, Il6 mRNA was 
significantly increased 37-fold in epididymal fat from mice with KPC tumors 
(Figure 2.10 C) and although not significant likely from increased variation and 
smaller sample size, a trend in increased Il6 was observed in muscle (6.4-fold, 
p=0.06) and liver (8.5-fold, p=0.1) from KPC tumor-bearing mice (Figure 2.10 C). 
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In contrast, Il6r mRNA was significantly increased in the quadriceps (8.9-fold) 
and liver (2.6-fold) but unchanged in the adipose tissue from KPC tumor mice 
(Figure 2.10 D). Interestingly, compared to KPC tumors, Il6 mRNA was increased 
in the KPC IL-6KO tumors (Figure 2.10 E), yet tumor Il6r mRNA was actually 
decreased in KPC IL-6KO tumors (Figure 2.10 F). Since changes in Il6 and Il6r 
mRNA expression were only observed in muscle and fat of KPC tumor-bearing 
mice, I investigated in more detail the source of these altered gene expressions 
by dissociating the tissue and analyzing the mononuclear cell fractions (MNC) in 
no tumor and KPC tumor-bearing mice. Compared to no tumor mice, Il6 mRNA 
expression was unchanged in the muscle MNC fraction from KPC tumor-bearing 
mice while unexpectedly; it was reduced in the fat MNC fraction from KPC tumor-
bearing mice (Figure 2.10 G). Il6r mRNA expression was increased, although 
modestly, in the muscle MNC fraction from KPC tumor-bearing mice and 
unchanged in fat compared to no tumor mice (Figure 2.10 H). These results 
indicate that the MNC fractions from muscle and fat are not significantly 
contributing to Il6 mRNA expression, but the muscle MNC fraction likely 
contributes in part to whole tissue Il6r mRNA expression in skeletal muscle. 
In contrast to the mRNA expression, there was no change in IL-6R protein 
expression in quadriceps and a significant increase of IL-6R protein in adipose 
tissue of KPC tumor mice (Figure 2.10 I and 2.10 J). Interestingly, only KPC mice 
had significantly increased STAT3 phosphorylation (pSTAT3) in quadriceps, 
while both tumor-bearing groups had increased pSTAT3 in fat (Figure 2.10 I and 
2.10 K). Immunofluorescence demonstrated IL6R protein in myofibers in all 
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groups (Figure 2.10 L, top) as well as robust staining in muscle blood vessels 
only in the KPC tumor mice (Figure 2.10 L, bottom). Strong IL-6 expression was 
observed in the fat from KPC tumor-bearing mice (Figure 2.10 M, top). In adipose 
tissue, visualization of the IL6R showed accumulation near cells positioned 
between adipocytes in all groups (Figure 2.10 M, bottom). Taken together, these 
results suggest tumor cell and adipose tissue IL-6 production contribute to 
systemic IL-6 levels and intricate crosstalk between stromal and tumor cells may 
be occurring in the KPC IL-6KO tumors requiring further investigation. 
Furthermore, these findings also implicate muscle as a primary source for 
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Figure 2.10. Evidence for an IL-6, IL6R circuit among tumor, adipose tissue 
and skeletal muscle in PDAC cachexia. Plasma from no tumor, KPC tumor 
and KPC IL-6KO tumor mice was harvested immediately prior to euthanasia and 
measured for IL-6 (A) and IL6R (B) protein expression using an ELISA. Isolated 
RNA from quadriceps, epididymal fat, and liver of mice was used to measure 
mRNA expression of Il6 (C) and Il6r (D) in tissues and presented as fold change 
versus no tumor mice. Isolated RNA from KPC and KPC IL-6KO tumors was used 
to measure mRNA expression of Il6 (E) and Il6r (F) in tumors and presented as 
fold change versus KPC tumors. To determine with increased detail the source of 
Il6 mRNA in fat and Il6r in muscle, tissues were dissociated and isolated RNA 
from the mononuclear cell fractions (MNC) was used to measure mRNA 
expression of Il6 (G) and Il6r (H).  Protein expression for IL6R and STAT3 
phosphorylation was quantified in the quadriceps and epididymal fat pads of mice 
using western blotting (I, J, K). Immunofluorescence showing the expression of 
IL6R protein (red) and nuclei (blue, DAPI) in the quadriceps muscle fibers of mice 
(L, top) and IL6R protein (red), the endothelial protein marker CD31 (green) and 
nuclei (blue, DAPI) to visualize IL6R expression in and around blood vessels in 
the quadriceps muscle of mice (L, bottom). IHC for IL-6 protein expression in the 
epididymal fat pads of mice (M, top) and immunofluorescence showing the 
expression of IL6R protein (red) and nuclei (blue, DAPI) in epidiymal fat (M, 
bottom); arrows indicate positive IL6R staining and dotted lines outline 
adipocytes denoted with the letter “a”. Error bars are standard deviation and 
significant differences between group means are shown in the charts. 
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2.3.8 Similar Changes to Tissue Wasting and Il6 and Il6r mRNA Expression are 
Observed with In Vitro Studies of the Tumor-Adipose-Muscle Crosstalk 
My results indicate that KPC tumors increase lipid accumulation, Il6r 
expression, and atrophy in skeletal muscle, and also activate lipolysis and Il6 
expression in fat (Figures 2.8-2.10). These effects on distant tissues could be 
mediated directly by tumor-derived products or indirectly through other cellular or 
molecular mediators. I tested whether products of KPC cells could affect muscle 
and fat directly. Indeed, KPC conditioned media (CM) was associated with 
myotube atrophy (Figure 2.11 A) and similar to in vivo results, increased Il6 and 
Il6ra mRNA expression was observed in myotubes after KPC CM treatment 
(Figure 2.11 B). KPC CM also increased 3T3L1 adipocyte lipolysis as measured 
by media glycerol concentration (Figure 2.11 C) and again, in parallel with my in 
vivo results, Il6 but not Il6ra mRNA expression was increased in 3T3L1 
adipocytes after treatment with KPC CM (Figure 2.11 D).  
KPC tumor-induced fat wasting produced increased circulating fatty acids 
and glycerol in vivo (Figure 2.9 B and 2.9 C). Moreover, increased Il6r mRNA 
expression was increased in muscle but IL6R protein was increased in fat. 
Extracellular lipids have been implicated in muscle dysfunction in diabetes and 
metabolic syndrome, and muscle IL6R expression, but the effects in PDAC 
cachexia are not described. I modeled the effect of the tumor-fat-muscle 
crosstalk axis in vitro using a series of CM swapping experiments. 3T3L1 
adipocytes were treated using KPC CM to induce lipolysis and the resulting 
3T3L1 CM was then used to treat myotubes and measure the effects on myotube 
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diameter. Myotubes treated with CM from 3T3L1 adipocytes after KPC CM 
treatment showed significant decrease in myotube diameter (Figure 2.11 E). To 
investigate the tumor-muscle-fat crosstalk axis, I treated C2C12 myotubes with 
KPC CM to induce atrophy and used the resulting C2C12 CM to treat 3T3L1 
adipocytes. Treatment of 3T3L1 adipocytes with C2C12 myotube CM after KPC 
CM treatment significantly induced lipolysis, which was determined by glycerol 
release into the media (Figure 2.11 F). Finally, I investigated whether 
physiological concentrations of IL-6, IL-6R or the combination could induce 
wasting in both myotubes and adipocytes. Myotube diameter was decreased in 
the presence of IL-6 (300 pg/mL) or IL6R (25 ng/mL) versus controls, however, 
the combination of IL-6 and IL6R produced the most severe myotube atrophy 
(Figure 2.11 G). Interestingly, IL-6 treatment of 3T3L1 adipocytes using 
physiological levels did not induce lipolysis, yet presence of the IL6R was 
sufficient to induce lipolysis with or without exogenous IL-6 (Figure 2.11 H). 
These results suggest that adipocytes are likely more sensitive to lipolysis in the 
presence of the IL6R and not IL-6 alone. These findings also support that IL-6 
and lipids can both mediate muscle loss, and further, that activation of adipose 
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Figure 2.11
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Figure 2.11. Modeling of IL-6, IL6R tumor-tissue crosstalk in vitro. C2C12 
myotubes were incubated with conditioned media (CM) from KPC tumor cells for 
48 hours and atrophy measured (A) and for 12, 24 and 96 hours and isolated 
RNA was used to measure mRNA expression of Il6 and Il6r at each time point 
(B). 3T3 adipocytes were incubated with KPC CM for one and three hours and 
glycerol was measured as a marker for lipolysis (C); 3T3 adipocyte RNA was 
harvested at each time point and used to measure mRNA expression of Il6 and 
Il6r (D). The tumor-fat-muscle crosstalk was investigated by incubating 3T3 
adipocytes with KPC CM and then using the 3T3 CM to treat myotubes for 48 
hours and measure atrophy (E). The tumor-muscle-fat crosstalk was investigated 
by treating myotubes for 12, 24 and 96 hours with KPC CM and then using the 
myotube CM to treat 3T3 adipocytes for 1 and 3 hours to measure lipolysis via 
media glycerol content (F). To decipher the effects of IL-6 and IL-6R in muscle 
and fat, myotubes and adipocytes were treated in vitro. Myotubes were incubated 
with differentiation media (DM), physiological levels of recombinant murine IL-6, 
physiological levels of recombinant murine IL6R, or the combination of IL-6 and 
IL6R for 48 hours and atrophy measured (G). 3T3 adipocytes were incubated 
with growth media (Control), physiological levels of recombinant murine IL-6, 
physiological levels of recombinant murine IL6R, or the combination of IL-6 and 
IL6R for 3 hours and media glycerol measured (H). Significant differences are 
shown in each chart.
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2.4 Summary 
Here I demonstrate novel tumor-tissue crosstalk in the macroenvironment 
of PDAC cachexia and further provide evidence of central roles for tumor cell-
derived IL-6 and IL-6 trans-signaling. In KPC tumor mice, both tumor cells and 
stromal cells in the tumor microenvironment produced IL-6; this signal was 
amplified distantly by production of IL-6 from adipose tissue and likely also in part 
from skeletal muscle in the “tumor macroenvironment” of the whole host body. 
Adipose tissue loss was proportionate to circulating IL-6 and halved by 
elimination of IL-6 from tumor cells, while muscle loss was abolished by tumor-
cell depletion of IL-6.  
These results indicate that adipose tissue was proportionately more 
sensitive to the effects of PDAC as measured by the induction of adipose 
wasting, lipolysis, and release of fatty acids and glycerol into the blood. Under 
these conditions, skeletal muscle exhibited steatosis, mitochondrial dysfunction, 
metabolic impairment, and wasting. As well, Il6r mRNA expression was 
increased by PDAC only in muscle and not fat, yet sIL6R protein accumulated in 
fat, and STAT3 phosphorylation indicated signaling in both peripheral tissue 
compartments. In vitro experiments showed similar Il6 and Il6r mRNA expression 
in muscle and fat cells after treatment with KPC CM. I also demonstrate that 
products of lipolysis (modeled with 3T3 CM after exposure to KPC CM) 
exacerbate muscle wasting and that products of muscle atrophy (modeled with 
C2C12 CM after exposure to KPC CM) can promote lipolysis. These results 
suggest that sIL6R is produced outside adipose tissue but accumulates in fat to 
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mediate IL-6 signaling and lipolysis in adipocytes and further, that skeletal 
muscle is a major source of this sIL6R in cachexia. Thus, providing an 
explanation of how adipose and muscle crosstalk in the presence of a tumor can 
augment wasting in each tissue (Figure 2.12)
	




Figure 2.12. Illustration of tumor-fat-muscle crosstalk in PDAC. Using my 
results this illustration summarizes my findings with respect to tumor, fat and 
muscle crosstalk in PDAC. Tumor cell-derived IL-6 affects both muscle and fat, 
leading to increases in fat and muscle wasting concomitantly with elevated 
circulating fatty acids. Increased circulating fatty acids promote myosteatosis, 
which is associated with increased oxidative stress in muscle. Increased IL6R 
production from muscle contributes to circulating levels of sIL6R to augment fat 
wasting. Therefore, in the presence of a tumor, muscle and fat act in a feed 
forward mechanism to augment cachexia.
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 Cachexia is associated with significantly altered muscle metabolism 
adding another stressor to the milieu of factors contributing to muscle wasting. 
Changes to metabolism modify energy demands in the tissue. Resting energy 
demand in approximately 50% of patients with cancer cachexia was increased by 
more than 100% of predicted values (Bosaeus, Daneryd, Svanberg, & Lundholm, 
2001). With increased resting energy expenditure, it is conceivable that diet 
alone may be inadequate for sufficient energy and must be supplemented 
through the breakdown of host tissues, the direct phenotype defined by cachexia. 
Skeletal muscle and adipose tissues are both nutrient dense, where fat is a prime 
source for lipids and muscle a main source of amino acids. Among the amino 
acids, branch chain amino acids (BCAAs) are essential for anabolic processes. 
BCAAs are usually obtained from the diet however, during times of nutrient 
deprivation or disease, BCAAs can come from the catabolism of skeletal muscle 
(Cahill & Aoki, 1971). Changes in BCAA levels in muscle and plasma have been 
reported during cachexia (Eley, Russell, & Tisdale, 2007; O'Connell, 2013).  
Lipid metabolism is a crucial process for skeletal muscle metabolic 
homeostasis. Robust changes in gene expression of lipolytic and lipogenic 
pathways are concomitant with myosteatosis observed in muscle from KPC 
tumor-bearing mice (Figure 2.5), suggesting severe dysfunction of lipid 
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metabolism in muscle during PDAC. Alterations in both glucose and lipid 
metabolism in muscle can influence downstream processes including the TCA 
cycle and the ETC in mitochondria. For instance, during normal carbohydrate 
metabolism PDH enables glucose-derived pyruvate, to enter the TCA cycle for 
complete oxidation. However, if Akt activation is reduced, Pdk4 expression can 
increase as a result of increased activation of FOXO transcription factors, leading 
to inhibition of PDH and a shift toward FAO to generate ATP. Indeed, excessive 
FAs can overwhelm and exhaust the mitochondria in muscle, leading to 
myosteatosis, mitophagy and reduced efficiency of mitochondrial metabolism. 
Evidence for these exists in Figure 2.8 where aberrant SDH reaction patterning 
was observed, indicating dysfunctional mitochondria localization and reduced 
oxidative potential. Mitochondrial exhaustion is associated with incomplete FAO. 
This occurs when oxidation of FA begins in mitochondria but due to insufficient 
levels of CoA and FAD, mitochondria cannot complete this process. This 
situation of “mitochondrial overload” can be characterized by elevated levels of 
medium and short chain acyl-carnitines (Muoio & Koves, 2007; Muoio & Neufer, 
2012). Thus, illustrating the delicate balance between glucose and fatty acid 
metabolic pathways, mitochondria dysfunction and atrophy in skeletal muscle. 
Deletion of tumor cell-derived IL-6 resulted in reduced inflammation, 
attenuated fat wasting and decreased myosteatosis (Chapter 2). This suggests 
the influence of tumor IL-6 on inflammation and adipose lipolysis may play a 
major role in muscle dysmetabolism, especially regarding the accumulation of 
lipids, in PDAC cachexia. Therefore, I aim to investigate the alterations and 
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interplay of BCAA metabolism, FAO, and glycolysis in skeletal muscle during 
PDAC associated cachexia. Furthermore, I report the effects of deleting tumor 
cell-derived IL-6 on these metabolic pathways. 
 
3.2 Materials and Methods 
3.2.1 Animal Models 
 Tissue for metabolic analyses was obtained from mice used in 
experiments described in Chapter 2. For animal use, euthanasia and skeletal 
muscle excision please refer to the relevant methods reported in Chapter 2. 
 
3.2.2 Sample Preparation for NMR 
Plasma samples for NMR analysis were prepared diluting 100 ml of 
plasma with 500 ml of deuterated phosphate buffer solution (pH = 7.4) containing 
2,2,-dimethyl-2-silapentane-5-sulfonate sodium salt (DSS) with a final 
concentration of 0.5 mM to be used as a chemical shift and quantitation 
reference.  The solution was then filtered through a 10 KDa, molecular weight 
cutoff filter to remove the proteins.  Samples were placed in 5 mm NMR tube for 
analysis.   Gastrocnemius muscle tissues for NMR analysis were prepared 
according to the methanol/chloroform water procedure described by Beckonert 
et. al. (Beckonert et al., 2007).  Tissue samples of approximately 100 mgs were 
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3.2.3 Sample Preparation for Mass Spectrometry 
Samples for targeted mass spectrometry analysis were conducted using 
the Biocrates Absolute IDQ kit (Biocrates, Innsbruck, Austria). Each plate 
contains 16 wells reserved for selected internal standards to optimize the 
metabolite quantification. For serum analysis, 10 ml aliquots were loaded directly 
into the 96 well plate followed by derivatization and extraction per vendor 
protocols. Muscle tissue was prepared according to vendor protocols (Biocrates, 
Preparation of Tissue and Feces Samples for Metabolic Phenotyping, version 
1.0).   
 
3.2.4 NMR Data Collection 
NMR data were acquired on a Bruker Advance III 700MHz NMR 
spectrometer with a TXI triple resonance probe operating at 25C. Spectra were 
collected with a 1D NOESY pulse sequence covering 12 ppm. The spectra were 
digitized with 32768 points during a 3.9 second acquisition time. The mixing time 
was set to 100 ms and the relaxation delay between scans was set to 2.0 
seconds.   
 
3.2.5 NMR Data Processing 
The data were processed using Advanced Chemistry Development 
Spectrus Processor (version 2016.1, Toronto, Canada).  The spectra were zero 
filled to 65536 points, apodized using a 0.3Hz decaying exponential function and 
fast Fourier transformed. Automated phase correction and 3rd order polynomial 
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baseline correction was applied to all samples.  Metabolite concentrations were 
quantified using the Chenomx NMR Suite (version 8.2, Edmonton, Canada). The 
DSS-d6 was used as a chemical shift and quantification reference for all spectra 
and was set to a chemical shift of 0.00 and a concentration of 500 µM.  
Quantitative fitting of each spectrum was carried out in batch mode, followed by 
manual adjustment for some spectra to correct for errors arising from spectral 
overlap. For tissue samples, the final concentrations were normalized based on 
the weight of the tissue used to prepare each sample. The quantification of 
glycogen in muscle and liver tissue was carried out using spectral integration 
rather than spectral fitting with the Chenomx software. As glycogen is a 
heterogeneous polysaccharide of different chain lengths, the NMR signals are 
composed of overlapping peaks in specific windows of the spectrum. The 
integration range from 5.37 to 5.43 ppm was used and the concentrations are 
given in spectral intensity units.    
 
3.2.6 Mass Spectrometry Data Collection 
This Biocrates AbsoluteIDQ p180 assay quantifies 188 metabolites from 
five chemical classes: acylcarnitines, amino acids, biogenic amines, hexoses 
(sum of hexoses), PCs, and sphingomyelins (SMs). Data were collected on an 
AB Sciex 4000 QTRAP coupled to an Acquity UPLC system with the selective 
mass-spectrometric detection using multiple reaction monitoring (MRM) pairs.  
The amino acids and biogenic amines were detected using and LC-MS/MS 
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method and the lipid species were detected using a flow injection analysis (FIA) 
MS/MS method per vendor-defined settings.   
 
3.2.7 Mass Spectrometry Data Analysis 
Data analysis including normalization (tissue weight) for quantification of 
metabolite concentrations and quality assessment were performed with the 
MetIDQ software package, which is an integral part of the AbsoluteIDQ kit. The 
metabolite concentration of each metabolite in each experimental condition was 
compared with the measurement detection limit specifications as reported by the 
manufacturer of the AbsoluteIDQ p180 kit (Biocrates). A metabolite was excluded 
from further analyses if its concentration measurement data did not meet all of 
the following criteria: (1) minor of 20% of missing values (non-detectable peak) 
for each quantified metabolite in each experimental group (2) 50% of all 
measured sample concentrations for the metabolite had to be above the limit of 
detection (LOD). 
 
3.2.8 Western Blotting 
Tissue protein lysates were made by homogenizing snap frozen tissue in 
ice cold RIPA buffer (Harlow & Lane, 2006) using a Polytron PT 10/35 
homogenizer with PCU 11 controller (Kinematica; Luzern, Switzerland). Protein 
lysate concentration was measured using the PierceTM BCA Protein Assay Kit 
(PI23228, Thermo Scientific; Waltham, MA USA). Protein lysate was then added 
1:1 to 2X sample buffer (125 mM Tris; pH 6.8, 4% (w/v) SDS, 20% glycerol, 100 
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mM DTT, 0.02% (w/v) bromophenol blue) and heated at 95°C for five minutes. 
Proteins were then separated via SDS-PAGE by loading 30 µg of protein from 
each sample into wells on a 4-15% CriterionTM TGXTM gel (5671084, Bio-Rad; 
Hercules, CA, USA) in running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) 
at 140 volts for one hour using a Power Pac HC (Bio-Rad; Hercules, CA, USA). 
The proteins were transferred to 0.2μm nitrocellulose membranes (1620233, Bio-
Rad; Hercules, CA, USA) in ice-cold transfer buffer (25 mM Tris, 192 mM glycine, 
20% (v/v) methanol, pH 8.3) at 100 volts for thirty minutes. Membranes were 
blocked using Sea Block (37527, Thermo Scientific; Waltham, MA USA) for one 
hour at room temperature on a shaker table. Proteins were detected using 
antigen specific primary antibodies, anti-Pdk4 (ab214938, Abcam; Cambridge, 
MA, USA) diluted 1:1000 in Sea block with 0.1% Tween 20 (BP337-500, Fisher 
Scientific; Waltham, MA USA) and incubated with the membranes overnight at 
4°C. Membranes were then washed twice with PBS and primary antibodies were 
visualized using florescent DyLightTM secondary antibodies (Cell Signaling; 
Danvers, MA, USA) with specificity against the primary antibodies and imaged on 
an Odyssey CLx (LiCor; Lincoln, NE, USA). The quantification of target proteins 
was done by normalizing target protein expression to the loading control protein 
expression (α-tubulin) specific to each membrane using Image Studio version 4.0 
(LiCor; Lincoln, NE, USA). Normalized protein expression was then presented as 
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3.2.9 Gene Expression Analyses 
 Evaluation of gene expression was performed using fold-change as 
measured in the RNA sequencing analyses described in Chapter 2.2.10. For 
mRNA extraction refer to the relevant methods in Chapter 2.2.10. Differentially 
expressed genes were selected as having a fold-change of ≥1.5 and an FDR of 
 ≤ 0.05. Differentially expressed genes were then analyzed using Ingenuity 
Pathway Analysis (IPA) to determine specific changes in known metabolic 
pathways. Gene expression was referenced against established metabolic 
signaling networks contained within the IPA software.  
 
3.2.10 Statistical Analysis 
Statistical comparison of metabolites for each of the groups was carried 
out in GraphPad Prism (GraphPad, La Jolla, CA) using a one-way ANOVA with 
Tukey’s multiple comparison test. Protein expression as measured by western 
blotting was compared between groups using a one-way ANOVA with Tukey’s 
multiple comparison test. Please refer to the statistical analysis in the methods 
section of Chapter 2.2.10 for detailed analysis of RNA-sequencing. Briefly, 
differential expression analysis was performed using edgeR and the false 
discovery rate (FDR) was computed from p-values using the Benjamini-Hochberg 
procedure. Differentially expressed genes were determined as having a fold 
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3.3 Results 
3.3.1 Deletion of Tumor Cell-derived IL-6 Mitigates Changes to Global Metabolic 
Expression Profiles in Plasma  
 A representation of the overall changes to the metabolic expression 
profiles in plasma from KPC and KPC IL-6KO tumor-bearing mice versus no tumor 
mice are depicted in the heatmap in Figure 3.1. The serum metabolite data 
presented in Figure 3.1 quantifies 187 metabolites from the targeted MS panel 
and 31 metabolites included in the NMR platform. Data are presented as Z-
scores with K-nearest neighbor clustering. These results show significant 
changes in metabolite levels in mice bearing KPC tumors, while metabolite levels 
in KPC IL-6KO tumor-bearing mice more closely resemble those of mice without 
tumors (Figure 3.1). In the following analyses, I present metabolomic and gene 
expression data representing the most severely affected metabolic pathways in 











	 	 83 
 
Figure 3.1. Deletion of tumor cell-derived IL-6 mitigates changes to plasma 
metabolites. Overall assessment of plasma metabolites in No Tumor, KPC 
Tumor and KPC IL-6KO Tumor bearing mice. Increased metabolite expression 
(red) and decreased metabolite expression (blue) are presented as a comparison 
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3.3.2 Tumor Cell-derived IL-6 is Associated with Increased BCAA Oxidation in 
Skeletal Muscle  
 In cachexia, changes to BCAA oxidation in muscle have been reported in 
the presence of tumors. Therefore, I investigated the BCAA oxidation pathway in 
skeletal muscle of mice with PDAC. BCAA oxidation requires the coordination of 
multiple signaling pathways including activation of the ubiquitin/proteasome 
pathway for the degradation of large peptides and the activation of the branched-
chain alpha-keto acid dehydrogenase complex (BCKDH) for oxidation of BCAAs 
into acetyl-CoA and succinyl-CoA for use in the TCA cycle (Figure 3.2 A). The E3 
ligase muscle RING-finger protein-1(Murf1) encoded by the Trim63 gene plays a 
crucial role in the poly-ubiquitination of peptides targeting them for degradation in 
the proteasome (Figure 3.2 A). The subunits Bckdha and Bckdhb are 
components of the BCKDH and activation of the branched chain keto acid 
dehydrogenase kinase (Bckdk) inhibits function of the BCKDH (Figure 3.2 A). 
BCAA quantification in plasma (Figure 3.2 B) and muscle (Figure 3.2 C) showed 
increases in all three (leucine, isoleucine and valine) BCAA in both plasma and 
muscle of KPC tumor bearing mice versus no tumor mice. No significant increase 
in BCAAs was observed in plasma or muscle of KPC IL-6KO tumor bearing mice 
(Figure 3.2 B and 3.2 C).   
 Ingenuity Pathway Analysis (IPA) in combination with previously obtained 
RNA-sequencing data (Chapter 2) from this tumor model revealed significant 
alterations to pathways involved in BCAA metabolism and amino acid transport in 
muscle of KPC tumor mice. Differential expression of genes involved in BCAA 
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metabolism was observed including down-regulation of Bckdk and up-regulation 
of Trim63, Bckdha, and Bckdhb (Figure 3.2 D). Additionally, two of three genes 
identified in the BCAA transport pathway were up regulated (Figure 3.2 E). 
Multiple down-regulated (Figure 3.2 F, top) and up-regulated (Figure 3.2 F, 
bottom) genes important in amino acid transport were identified. Transportation 
of amino acids involves additional chaperone and membrane transporter 
proteins. Genes encoding these proteins were also differentially expressed in 
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Figure 3.2 BCAA oxidation is increased in the muscle of KPC tumor mice. 
Key molecules in the ubiquitin proteasome mediated catabolism of proteins and 
the oxidation of BCAAs (leucine, isoleucine and valine) are depicted (A). Plasma 
and muscle BCAAs were measured (B and C). Using previously obtained 
RNAseq data from these mice, differentially expressed genes(DEG) (fold-change 
≥ 1.5 and FDR ≤ 0.05) were referenced against curated pathway gene sets from 
the Gene Set Enrichment Analysis (GSEA) database and DEG genes involved in 
BCAA metabolism (D), BCAA transport (E), amino acid transport (F) and amino 
acid binding (G) are shown. Bars shaded red indicate genes coding for 
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3.3.3 Glucose Oxidation and TCA Cycle Activity are Decreased in KPC Tumor 
Mice 
  Pyruvate sits at a metabolic nexus where it can be reduced to lactate with 
the formation of NAD+ or it can enter the TCA cycle to complete the oxidative 
process. Increased lactate formation can occur during conditions of impaired 
glucose regulation, which is associated with myosteatosis. Therefore, I 
investigated changes in the concentrations of glucose, pyruvate, and lactate in 
plasma and skeletal muscle concomitant with determination of changes to 
relevant gene expressions in the glycolysis pathway. Using the IPA established 
glycolysis pathway, a number of key enzymes in glycolysis had altered activity in 
the muscle of KPC tumor-bearing mice. Specifically, in the muscle of KPC tumor-
bearing mice, increases in glucose-6-phosphate and fructose-bisphosphate 
aldolase activity were identified (Figure 3.3 A), while decreased activity of triose-
phosphate isomerase, phosphoglycerate mutase, and phophospyruvate 
hydratase were predicted (Figure 3.3 A). Multiple genes were also identified as 
directly or indirectly interacting with these intermediates (Figure 3.3 A) These 
changes were almost eliminated when IL-6 was deleted from the tumor however, 
expression of the thyroid hormone responsive (Thrsp) gene was significantly 
decreased in both KPC and KPC IL-6KO	(Figure 3.3 A and 3.3 B). Interestingly, 
this gene is involved in regulating lipogenesis and the synthesis of triacylglycerol 
from medium length fatty acids. Plasma glucose was decreased in both KPC and 
KPC IL-6KO tumor mice (Figure 3.3 C) and decreased plasma pyruvate was only 
observed in KPC versus KPC IL-6KO tumor mice (Figure 3.3 C), while plasma 
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lactate was only decreased in the KPC IL-6KO group (Figure 3.3 C). Muscle 
lactate was only increased in KPC tumor mice (Figure 3.3 D).  
 The interactions between carbohydrate and fatty acid metabolism in 
muscle are regulated by the pyruvate dehydrogenase (PDH) complex and the 
pyruvate dehydrogenase kinase (PDK). In muscle, Pdk4 is the predominant 
isoform and when increased, inhibits PDH activity, resulting in impaired 
mitochondrial oxidation of glucose and a shift toward increased reliance on FAO 
to fuel the TCA cycle. The subunit Pdha is a crucial component of the PDH 
complex and encoded by the Pdha gene. In muscle of KPC tumor mice, Pdha 
expression was significantly decreased (-1.28-fold) while expression of the Pdk4 
gene was increased (12.13-fold) versus no tumor mice. Furthermore, muscle 
Pdk4 protein expression was increased in KPC tumor mice alone (Figure 3.3 E 
and 3.3 F). These results suggest that glycolysis in muscle is significantly 
affected by the presence of a tumor and glucose oxidation is likely decreased 
with downstream effects on TCA cycle function. 
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Figure 3.3  
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Figure 3.3 Glycolysis is altered in the muscle of KPC tumor mice.  Ingenuity 
Pathway Analysis (IPA) was used to analyze the glycolysis pathway using my 
previously obtained RNAseq data in muscle. Multiple molecules important in 
glycolysis were predicted to be differentially regulated in the muscle of KPC 
tumor mice (A) and these molecules were unchanged in the muscle of KPC IL-
6KO tumor mice (B). The metabolites Glucose, pyruvate and lactate are involved 
in glycolysis and were measured in plasma (C) and muscle (D) in mice. Pyruvate 
dehydrogenase kinase 4 (Pdk4) is a key regulator of the pyruvate 
dehydrogenase complex (PDH), which activation or inhibition of PDH determines 
the fate of pyruvate oxidation and acetyl-CoA production. Pdk4 protein 
expression in the muscle of mice was measured using western blotting (E and 
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3.3.4 KPC Tumor Mice have reduced TCA cycle activity and decreases in key 
metabolites important for TCA cycle function. 
 Metabolomic analysis of key TCA cycle intermediates revealed differences 
in citrate, succinate, fumurate and malate. In plasma, acetate, fumurate and 
malate were significantly decreased in both KPC and KPC IL-6KO tumor groups 
(Figure 3.4 A, 3.4 D, and 3.4 E). Plasma citrate was increased in the KPC tumor 
group alone (Figure 3.4 B). There were no changes observed in succinate levels 
in either group (Figure 3.4 C). Interestingly, while changes in plasma metabolites 
were measured, skeletal muscle metabolite levels remained largely unchanged 
(Figure 3.4 A-E). To determine if key enzymes important for TCA cycle function 
were affected, RNA-sequencing data were cross-referenced with the established 
TCA cycle pathway genes in IPA. While aconitate hydratase (also known as 
aconitase) was unchanged, the majority of genes involved in its activity were 
down regulated in muscle from KPC tumor-bearing mice (Figure 3.4 F). In KPC 
tumor-bearing mice, decreased activity was predicted for isocitrate 
dehydrogenase and succinate dehydrogenase in muscle concomitantly with 
decreased expression of genes involved in the activity of these enzymes (Figure 
3.4 F). Interestingly, an increase in 2-ketogluturate dehydrogenase complex was 
predicted to be increased in muscle from KPC tumor-bearing mice (Figure 3.4 F). 
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Figure 3.4. Conventional function of the TCA Cycle is significantly changed 
in the muscle of KPC tumor mice. Intermediate metabolites involved in the 
TCA Cycle were measured in plasma and muscle (A-E). Ingenuity Pathway 
Analysis (IPA) was used to analyze key molecules in the TCA Cycle using my 
previously obtained RNAseq data in muscle. Multiple molecules important in TCA 
Cycle function were predicted to be differentially regulated in the muscle of KPC 
tumor mice (F) and these changes were largely absent in the muscle of KPC IL-
6KO tumor mice (G). Error bars are standard deviation and differences are 
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3.3.5 KPC Tumor-bearing Mice have Altered Muscle Lipid Metabolism in 
Association with Accumulation of Acylcarnitines. 
 The significant loss of adipose tissue and resulting myosteatosis 
associated with KPC tumors (Chapter 2) is likely contributing to changes in 
muscle metabolism. To investigate this, I compared gene expression data for 
known lipid metabolism pathways with measurements of plasma and muscle 
acylcarnitines. Beta-oxidation was significantly altered in the muscle of KPC 
tumor-bearing mice, specifically by changes in expression of genes involved in 
long-chain-fatty-acid-CoA ligase, dodecenoyl-CoA D-isomerase, enoyl-CoA 
hydratase, and acetyl-CoA C-acyltransferase (Figure 3.5 A). Muscle of KPC IL-
6KO did not show any significant changes in the expression of these genes 
(Figure 3.5 B).  
Multiple genes involved in the activity of acyl-CoA synthetase long chain 
family member 5 (Ascl5) and acyl-CoA synthetase long chain family member 6 
(Ascl6), important for triacylglycerol synthesis, were differentially regulated in the 
muscle of KPC tumor mice (Figure 3.5 C). Again, these changes in gene 
expression were undetected in muscle from KPC IL-6KO tumor mice (Figure 3.5 
D). Acyl-CoA hydrolysis is important for the metabolism of fatty acids and is 
subsequently affected by changes in lipid metabolism. In the muscle of KPC 
tumor mice, palmitoyl-CoA hydrolase was significantly altered and changes in 
gene expression, in particular decreases in Ces1e, Acot11, Them4, Ppt1 and 
increases in Acot2, Acot4 gene expression were measured (Figure 3.5 E). Acyl-
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CoA hydrolysis was largely unaltered in muscle of KPC IL-6KO tumor mice (Figure 
3.5 F).  
Finally, measurements of plasma and muscle acylcarnitines supported the 
changes in gene expression observed in the fatty acid activation and acyl-CoA 
hydrolysis pathway analyses. KPC tumor mice had elevated acylcarnitines, 
specifically C4 and C5 and C12-C18 compared to no tumor mice (Figure 3.5 G). 
In muscle, only the acylcarnitines C5 and C16 were elevated in KPC tumor mice 
and interestingly, C16 was also increased in KPC IL-6KO tumor mouse muscle 
when compared against no tumor mice (Figure 3.5 H). The increase in C5 
acylcarnitine is expected since BCAA oxidation was also increased and 
increased C5 acylcarnitine is a prominent marker of BCAA catabolism (Lerin et 
al., 2016; Newgard, 2017). Taken together, these results show significant 
alterations to muscle lipid metabolism especially with regards to beta-oxidation 
and acyl-CoA hydrolysis. These data also suggest that tumor IL-6 augments 
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Figure 3.5. Lipid metabolism is significantly altered in the muscle of KPC 
tumor mice. Ingenuity Pathway Analysis (IPA) was used to analyze beta-
oxidation (A and B), triacylglycerol synthesis (C and D), and Acyl-CoA hydrolysis 
(E and F) pathways in the muscle of KPC and KPC IL-6KO tumor mice using my 
previously obtained RNAseq data. Acylcarnitine levels were measured in plasma 
(G) and muscle (H) from KPC and KPC IL-6KO tumor mice and shown as fold 
change versus no tumor mice (dotted line). Significant differences from no tumor 
mice are indicated by * and differences from KPC IL-6KO tumor mice are 
indicated by ∆, where * or ∆ is p<0.05, ** is p<0.001 and *** or ∆∆∆ is p<0.0001. 
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3.4 Summary 
Deletion of tumor cell-derived IL-6 mitigated the changes to metabolism 
observed in KPC tumor mice. Mice bearing KPC tumors had increased protein 
catabolism as evident from the robust increase in the E3 ubiquitin ligase Trim63 
and elevated BCAAs in both plasma and muscle. Increased BCAAs were also 
accompanied by changes in expression of genes important for BCAA oxidation 
and transport. Expression was also altered in genes responsible for the 
chaperoning and transport of amino acids. These results indicate significant 
alterations to protein catabolism and BCAA metabolism in skeletal muscle 
associated with PDAC.  
Glycolysis was significantly altered in KPC tumor mice specifically with 
predicted increases in glucose-6-phosphate isomerase and fructose-
bisphosphate aldolase function and decreased function of trios-phosphate 
isomerase, phosphoglycerate mutase, and phosphopyruvate hydrolase. Changes 
in gene expression affecting these enzymes were not observed in KPC IL-6KO 
tumor mice. Furthermore, changes in metabolites associated with glycolysis 
including glucose, pyruvate and lactate were primarily observed in the plasma of 
tumor bearing mice. Skeletal muscle lacked any significant changes in these 
metabolites and remained largely homeostatic across groups. The expression of 
Pdk4, a primary inhibitor of the PDH complex, was increased in the muscle of 
KPC tumor mice. This result, along with changes in glycolysis activity suggests 
that oxidative metabolism is limited with glucose going to lactate rather than 
entering TCA cycle. 
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Indeed, differentially expressed genes alluded to changes in key enzymes 
in the TCA cycle in the muscle of KPC tumor mice. Specifically, decreases in 
isocitrate dehydrogenase and succinate dehydrogenase were predicted. Again, 
plasma analyses showed the most robust changes to TCA cycle metabolites 
including citrate, fumurate and malate, with muscle remaining homeostatic. 
Lipid metabolism was the most severely altered amongst the pathways 
analyzed. Changes to beta-oxidation, triacylglycerol synthesis and acyl-CoA 
hydrolysis were distinct in the muscle of KPC tumor mice. Additionally, KPC 
tumor mice had significant increases in acylcarnitines in both plasma and 
muscle. These changes were absent in the plasma and muscle of KPC IL-6KO 
tumor mice with the exception of the increase in the acylcarnitine C16 in muscle. 
Taken together, these results suggest that significant changes occur to muscle 
metabolism in the presence of PDAC, with perhaps the lipid metabolism being 
the most severely affected. 
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CHAPTER 4: DELETION OF PKC THETA ATTENUATES MUSCLE WASTING 
IN PDAC-ASSOCIATED CACHEXIA 
 
4.1 Overview 
PKCq belongs to the nPKC subfamily and is the predominant PKC 
isozyme in skeletal muscle (Osada et al., 1992). PKC has been linked to a 
variety of pathologies including cancer (Gu et al., 2019; Isakov, 2018; Motegi et 
al., 2005; J. Wu et al., 2016; Yao et al., 2019), neuropathies (Kurumatani et al., 
1998; Shukla, Banerjee, & Tripathi, 2018; Tsubaki et al., 2015), muscular 
dystrophy (Dobrowolny et al., 2018; Kumar, Shanmugasundaram, Sundaram, & 
Anandaraj, 2002; Lozanoska-Ochser et al., 2018), and metabolic diseases such 
as type-2 diabetes and obesity (Y. Chen et al., 2019; Egan Benova et al., 2019; 
Itani, Pories, Macdonald, & Dohm, 2001; C. H. Liu et al., 2018; Serra et al., 
2003). More specifically, the association of PKC-theta (PKCq) ablation with 
decreased pathogenicity in muscle from models of type-2 diabetes (T2D) and 
Duchenne’s muscular dystrophy (DMD) is perhaps the most relevant to cancer 
cachexia. Both T2D and DMD are characterized in part by chronic inflammation, 
myosteatosis and muscle atrophy (Dahlqvist et al., 2019; Janssens et al., 2015; 
Jonkers, van Loon, Nicolay, & Prompers, 2013; Srivastava, Yadav, Mukherjee, 
Pal, & Sinha, 2017). In the mdx model of muscular dystrophy, ablation of PKCq 
reduced muscle degeneration and inflammation while increasing muscle 
regeneration (Madaro et al., 2012; Marrocco et al., 2017). Deletion of PKCq in 
skeletal muscle also reduced myosteatosis and muscle insulin resistance in mice 
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fed a high fat diet (Peck et al., 2018), while supplementation of excess fatty acids 
in rats was associated with elevated muscle lipid accumulation, activation of 
PKCq and increased insulin resistance (Griffin et al., 1999). Taken together, 
these results present a clear relationship between inflammation, lipid 
accumulation and PKCq in diseases associated with muscle wasting. 
Studies investigating lipid accumulation in muscle have also identified the 
association between elevated plasma fatty acids and increased muscle DAG 
content, an important secondary messenger for complete activation of PKCq 
(Boden, 2008; Itani, Ruderman, Schmieder, & Boden, 2002). As already shown, 
KPC tumor-bearing mice have significant lipolysis with increases in plasma fatty 
acids and myosteatosis. Therefore, I aim to investigate the effects of PDAC -
induced myosteatosis on PKCq activation in skeletal muscle, which has not been 
previously reported. I also investigate the effects of PKCq deletion on muscle and 
fat wasting in PDAC. 
 
4.2 Materials and Methods 
4.2.1 Animal Models 
Experiments that included mice were approved by and performed in 
accordance with the Indiana University School of Medicine Institutional Animal 
Care and Use Committee. The gene encoding the PKCθ protein is Prkcq. Prkcq-/- 
mice were purchased from Jackson laboratories (004658, Bar Harbor, Maine, 
USA) and bred in the animal facility at IUSM. Pups were weaned at 21-days, 
separated by sex, and group-housed in a barrier facility with ad libitum access to 
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autoclaved food (Envigo: Huntingdon, Cambridgeshire, United Kingdom), sterile 
water, maintained on a 12hr light/dark cycle and allowed to acclimate to the 
facility for four weeks. Wild type mice C57BL/6J mice (000664, Jackson 
Laboratory; Bar Harbor, Maine, USA) were also purchased and bred alongside 
the Prkcq-/- mice to control for environmental and breeding factors. 
 
4.2.2 Orthotopic Implantation of KPC tumor cells 
 Detailed methods on this procedure have been explained previously in 
section 2.2.8. 
 
4.2.3 Euthanasia of Mice and Excision of Tissues 
 Detailed methods regarding euthanasia and tissue excision are reported in 
section 2.2.9.  
 
4.2.4 Western Blotting 
Homogenization and preparation of quadriceps tissue protein lysates have been 
described in detail in section 2.2.11. Additionally, the western blotting protocol 
used in this chapter is also reported in section 2.2.11. Primary antibodies were 
purchased from Cell Signaling (Cell Signaling; Danvers, MA, USA) and used at a 
dilution of 1:1000 for phosphorylated PKCθ (#9377P), PKCθ (#13643S), PKCθ 
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4.2.5 Myotube Staining and Diameter Measurement and Muscle CSA 
 The proliferation and differentiation of myoblasts into myotubes is 
described in section 2.2.3. Fixation, sectioning and fiber CSA quantification is 
reported in section 2.2.15. Plasma was isolated from KPC tumor-bearing mice 
and used to treat mature myotubes at a concentration of 2% of final volume in 
combination with vehicle (PBS) or the PKCθ inhibitor Sotrastaurin (S2791, 
Selleck Chemicals; Houston, TX, USA) at a concentration of 500 nM for 48 
hours. Myotubes were then fixed, visualized and diameter quantified using 
established protocols in section 2.2.15. 
 
4.2.6 Measurement of Muscle Force Production In Vivo 
 Muscle force production in vivo was measured using a 1300A dual-mode 
force transducer with footplate and data analyzed using the 605A dynamic 
muscle data acquisition and analysis system from Aurora Scientific (Aurora, ON, 
Canada). Briefly, mice were anesthetized using 2-4% isoflurane and place in a 
supine position and the right hind limb was attached to the footplate of the force 
transducer. The foot and knee were secured in such a way that formed an 
approximate 90° angle between the foot, knee and hip of the mouse. Stimulation 
of the lower limb and plantar flexion of the foot was achieved by the placement of 
electrodes into the medial-posterior thigh near the sciatic nerve. Electrical 
stimulation was supplied in volts to the electrodes via a 701C electrical stimulator 
from Aurora Scientific. Stimulation was gradually increased until a maximum 
force production was reached, where further increases in stimulation did not 
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increase force production. Then, the voltage was increased by 20% to produce a 
supramaximal stimulation ensuring complete stimulation of the hind limb 
muscles. The muscles were then stimulated for durations of 0.2 milliseconds 
(ms) at frequencies of 10, 25, 40, 60, 80, 100, 125, and 150 Hz. Force was 




4.3.1 PKCθ Activation is Increased in Muscle from KPC Tumor Mice and 
Inhibition of PKCθ Maintains Myotube Diameter in the Presence of Atrophic 
Stimuli 
 PKCθ activation has been implicated in a number of pathologies and 
conditions associated with myosteatosis. Thus, given the accumulation of lipids 
observed in muscle of KPC tumor mice, PKCθ activation was measured in 
muscle. This was accomplished through quantification of PKCθ phosphorylation 
at threonine 538 (Thr538), which is located in the activation loop of PKCθ and 
phosphorylation of Thr538 is specific to this isozyme for activation (X. Wang, 
Chuang, Li, & Tan, 2012). To further verify activation of PKCθ, measurement of 
the phosphorylation of downstream PKCθ substrates was done using western 
blotting. Phosphorylation of PKCθ was increased in muscle from KPC but not 
KPC IL-6KO tumor mice (Figure 4.1 A and 4.1 B). Moreover, measurement of the 
phosphorylation of PKCθ substrates showed increases in PKCθ substrate 
phosphorylation in KPC but not KPC IL-6KO muscle (Figure 4.1 C and 4.1 D). 
	
	 	 106 
Given that KPC tumor mice had significant myosteatosis and atrophy when 
compared with KPC IL-6KO mice (Chapter 2), these results suggests that the 
degree of myosteatosis is associated with PKCθ activation and muscle atrophy. 
 Thus, I investigated the effects of inhibiting PKCθ in myotubes in vitro on 
myotube atrophy when presented with an atrophic stimulus. Myoblasts were 
differentiated into myotubes and treated with 2% KPC tumor mouse plasma in 
combination with a vehicle or the PKCθ inhibitor sotrastaurin for 48 hours (Figure 
4.1 E). Myotubes were then visualized using immunofluorescence for MHC 
(Figure 4.1 F) and myotube diameter measured. Myotubes treated with KPC 
tumor mouse plasma and vehicle had a significant decrease in myotube diameter 
compared to those treated with KPC mouse plasma and sotrastaurin (Figure 4.1 
F and 4.1 G). These results suggest that PKCθ is activated in muscle in the 
presence of PDAC tumors and the inhibition of PKCθ attenuates myotube 
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Figure 4.1. PKCq phosphorylation is increased in muscle of KPC tumor 
mice and inhibiting PKCq protects against myotube atrophy in vitro. 
Activation of PKCq in part requires its phosphorylation. Phosphorylation of PKCq 
was measured by western blotting in the quadriceps of mice (A and B). To 
further investigate if PKCq was activated, phosphorylation of PKCq substrates 
were measured in the quadriceps muscle of mice by western blotting (C and D). 
To investigate the effects of inhibiting PKCq on muscle wasting, C2C12 
myotubes were treated with 2% plasma from KPC tumor mice with or without the 
PKCq inhibitor Sotrastaurin (E). Myotubes were visualized using 
immunofluorescence for MHC and atrophy measured (F and G). Error bars are 
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4.3.2 Prkcq-/- Tumor Bearing Mice Have Increased Survival and Higher Muscle 
Force Production versus Prkcq+/+ Mice. 
 Prkcq is the gene encoding the PKCθ protein. Therefore, I used Prkcq-/- 
mice to investigate the effects of deleting PKCθ on survival, and muscle force 
production in vivo. Prkcq-/- KPC tumor mice although modest, had a significant 
increase in survival compared to Prkcq+/+ KPC tumor mice (Figure 4.2 A). Prkcq-/- 
KPC tumor mice showed no significant difference in tumor size versus wild type 
mice (Figure 4.2 B).  
 In vivo muscle force production was measured for tumor-bearing mice at 8 
days and 15 days after tumor cell implantation. There was no difference in 
normalized muscle force production between Prkcq+/+ and Prkcq-/- tumor-bearing 
mice at day 8 (Figure 4.2 C). Prkcq-/- tumor-bearing mice had significantly higher 
muscle force production compared to Prkcq+/+ KPC tumor mice at day 15 (Figure 
4.2 D). To assess changes to muscle force production within the specific groups, 
force production for day 8 and day 15 were compared directly for Prkcq+/+ and 
Prkcq-/- KPC tumor mice. Prkcq+/+ KPC tumor mice had a significant decline in 
muscle force production between day 8 and day 15 at stimulation frequencies of 
60-125 Hz (Figure 4.2 E). There was no difference in force production between 
day 8 and day 15 for Prkcq-/- KPC tumor mice (Figure 4.2 F). To verify that PKCθ 
expression was indeed ablated, mice were euthanized and PKCθ protein 
expression in the quadriceps muscle was measured. Prkcq+/+ no tumor and KPC 
tumor mice had PKCθ expression in muscle, which was undetectable in Prkcq-/- 
no tumor and KPC tumor mice (Figure 4.2 G). 
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Figure 4.2 
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Figure 4.2. Deletion of PKCq increases survival and is associated with 
increased muscle force production in vivo in KPC tumor bearing mice. KPC 
tumor-bearing mice ablated for the gene Prkcq-/-, which codes for the protein 
PKCq, had increased survival compared to Prkcq+/+ mice with tumors (A). Tumor 
size was not significantly different between Prkcq-/- and Prkcq+/+ mice (B). In vivo 
muscle force production was unchanged between wild type (Prkcq+/+) and Prkcq-/- 
tumor-bearing mice at 8 days after KPC tumor implantation (C),but was 
significantly changed at 15 days after KPC tumor implantation (D). Wild type KPC 
tumor bearing mice had a significant difference in muscle force production 
between day 8 and day 15 after tumor implantation (E), where the was no 
statistical difference in muscle force production between day 8 and day 15 in the 
Prkcq-/- tumor mice (F). To verify PKCq expression was abolished in mice, PKCq 
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4.3.3 Prkcq-/- KPC tumor mice have attenuated muscle wasting and decreased 
protein ubiquitination versus Prkcq+/+ KPC tumor mice. 
 Muscles were excised and weighed from mice to determine the severity of 
muscle wasting. Prkcq+/+ KPC tumor had significant loss of muscle mass for the 
quadriceps, gastrocnemius, tibialis and heart muscles compared to Prkcq-/- KPC 
tumor mice (Figure 4.3 A). Moreover, muscle fiber CSA and total protein 
ubiquitination were measured to verify the presence of muscle wasting. Cross 
sections from the quadriceps muscle were visualized using immunofluorescence 
for dystrophin (Figure 4.3 D). Prkcq+/+ KPC tumor mice had a significantly smaller 
average muscle fiber CSA when compared to Prkcq+/+ no tumor and Prkcq-/- KPC 
tumor mice (Figure 4.3 B). Prkcq+/+ KPC tumor mice also had a larger percentage 
of smaller CSA fibers, illustrated by a leftward shift in the frequency distribution 
curve, when compared against the other groups (Figure 4.3 D). Finally, protein 
ubiquitination was increased in Prkcq+/+ KPC tumor mice compared with Prkcq+/+ 
no tumor and Prkcq-/- KPC tumor mice (Figure 4.3 E and 4.3 F). Interestingly, 
Prkcq-/- no tumor mice had increased protein ubiquitination versus Prkcq+/+ no 
tumor mice (Figure 4.3 E and 4.3 F) and may indicate an underlying phenotype 
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Figure 4.3. Deletion of PKCq attenuates atrophy and protein ubiquitination 
in muscle of tumor bearing mice. Muscle wasting was measured in tumor 
bearing mice using tissue weight and fiber CSA analysis in the quadriceps 
muscle. At euthanasia, the quadriceps, gastrocnemius, tibialis and heart muscles 
were excised and weighed (A). Changes in muscle weights were verified using 
muscle fiber CSA analysis on quadriceps sections. Sections from the quadriceps 
muscle were reacted for dystrophin to visualize myofibers (D) and myofiber CSA 
was measured (B). Cumulative myofiber CSA measurements were pooled to 
visualize the frequency distribution, observing the classic leftward shift in the 
Prkcq+/+ tumor bearing group, indicative of a higher percentage of smaller fibers 
(C). total protein ubiquitination was measured in the quadriceps using western 
blotting (E and F). Error bars are standard deviation and statistical differences 












	 	 115 
4.4 Summary 
 PKCq is activated in diseases associated with myosteatosis and 
contributes to altered tissue metabolism and muscle atrophy. In the muscle of 
KPC tumor mice, phosphorylation of PKCq and PKCq substrates was increased 
compared to no tumor mice. Deletion of tumor cell IL-6 attenuated 
phosphorylation of PKCq and its downstream substrates. In vitro, the 
administration of the PKCq inhibitor Sotrastaurin rescued myotube atrophy during 
treatment with plasma from KPC tumor mice. 
 In vivo, deletion of Prkcq, the gene encoding PKCq, was associated with 
increased survival and higher muscle force production in tumor-bearing mice. 
Moreover, Prkcq-/- tumor mice had reduced loss of skeletal and cardiac muscle 
mass concomitantly with increased muscle fiber CSA when compared to Prkcq-/- 
tumor mice. Protein ubiquitination, a classic indication of increased protein 
catabolism via the ubiquitin proteasome, was decreased in the muscle of Prkcq-/- 
tumor mice comparatively. These results suggest that PKCq inhibition is an 
encouraging target in muscle for the improvement of muscle atrophy and force 
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CHAPTER 5: DISCUSSION 
 
5.1 Tumor, Adipose, Skeletal Muscle Crosstalk in PDAC Cachexia 
IL-6 production by tumor epithelial cells is largely unstudied in PDAC. My 
data indicate that a substantial number of human PDAC tumors exhibit 
expression of IL-6 in the epithelial compartment and further, that IL-6 is produced 
by a majority of established PDAC tumor cell lines. This has clear implications for 
PDAC tumor biology. Here, I demonstrate novel tumor-tissue crosstalk in the 
macro environment of PDAC cachexia and further provide evidence of central 
roles for tumor cell-derived IL-6 and IL-6 trans-signaling. In my studies, autocrine 
IL-6 production was not required for KPC tumor cell proliferation in vitro, although 
IL-6 null tumors in vivo were smaller. Blood levels of IL-6 are generally correlated 
with increased cachexia and mortality in patients with late stage PDAC, and IL-6 
production by fibroblasts and myeloid cells in the tumor microenvironment has 
been implicated in PDAC development and tumor growth, progression, 
metastasis and drug resistance (Holmer et al., 2014; Mace et al., 2018; Ohlund 
et al., 2017). I found that both the tumor cells and stromal cells in the tumor 
microenvironment expressed IL-6 in KPC tumor mice. KPC IL-6KO tumor cells 
were negative for IL-6 expression. Mice with IL-6KO tumors also exhibited 
reduced circulating IL-6, which was halved by the elimination of IL-6 from tumor 
cells. Adipose tissue loss was proportionate to circulating IL-6 in the tumor 
groups, since KPC IL-6KO tumor mice had approximately half as much plasma IL-
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6 and fat wasting versus KPC tumor mice. Interestingly, muscle loss was 
essentially abolished by tumor-cell depletion of IL-6.  
My investigation into tissue crosstalk showed that crosstalk between the 
tumor and adipose tissue acted to amplify IL-6 expression distantly, as adipose 
tissue had the highest Il6 mRNA expression amongst the tissues analyzed. 
Additionally, 3T3 adipocytes treated with KPC CM had increased Il6 mRNA 
expression, corroborating my in vivo tissue analyses. These results indicate that 
adipose tissue was proportionately more sensitive to the effects of PDAC as 
measured by the induction of adipose wasting, lipolysis, and release of fatty 
acids and glycerol into the blood. My findings are similar to those reported in 
human patients with cachexia. Adipose inflammation is noted in patients with 
cancer cachexia (Camargo et al., 2015), and furthermore, the magnitude of fat 
loss (~30%) exceeded that of muscle loss (7%) in patients on FOLFIRINOX for 
advanced disease (Kays et al., 2018), while only fat was lost in patients with 
PDAC on neoadjuvant therapy (Sandini et al., 2018).   
In the KPC tumor mice, the skeletal muscle exhibited steatosis, 
mitochondrial dysfunction, metabolic impairment, and wasting. The expression of 
Il6r mRNA was increased only in the muscle but not fat of KPC tumor mice, yet 
these mice accumulated soluble IL6R protein in fat. Again, in vitro experiments 
concurred with my in vivo findings as C2C12 myotubes treated with KPC CM had 
increased expression of Il6r mRNA. Il6r mRNA expression was unchanged in 
3T3 adipocytes treated with KPC CM. STAT3 phosphorylation was increased in 
both muscle and fat of KPC tumor mice, indicating signaling in both peripheral 
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tissue compartments. Deletion of tumor IL-6 mitigated most of these effects. 
These results suggest that skeletal muscle is a major source of the sIL6R in 
cachexia and its accumulation in fat likely mediates the effects of IL-6 signaling 
on adipocytes and furthers lipolysis.  
My observation of myosteatosis in the KPC tumor group proposes a role 
for lipid accumulation in muscle atrophy. I verify this using an in vitro approach 
with products of lipolysis (modeled with CM from KPC CM treated 3T3 
adipocytes) used to treat C2C12 myotubes. Myotubes treated with KPC 
stimulated 3T3 adipocyte CM had exacerbated wasting. Thus, increased lipolysis 
and IL-6 production from adipocytes as a result of PDAC offers an explanation of 
how adipose loss can lead to muscle wasting. Suggesting that PDAC cachexia is 
promoted in a feed forward mechanism, where tumor IL-6 promotes wasting of 
both fat and muscle, which stimulates crosstalk between fat and muscle via 
sIL6R and myosteatosis, which augments cachexia (Figure 2.9). Low skeletal 
muscle mass is predictive of mortality across diseases (Martin et al., 2013), 
which could be attributable to functional decline and respiratory or cardiac failure; 
however, the significance of fat loss is less clear. Indeed, the authors of a recent 
study discount adipose loss as participating in PDAC mortality, based upon 
feeding pancreatic enzymes to mice with pancreatic cancer and upon cross 
sectional body composition data in patients (Danai et al., 2018). Against that 
singular interpretation, however, are both clinical-correlative and mechanistic 
studies. Fat loss in the absence of muscle loss has been observed in cohorts of 
patients with PDAC (Sandini et al., 2018), (Kays et al., 2018), consistent with 
	
	 	 119 
these being separable phenomena, and higher rates of adipose loss are 
associated with mortality in PDAC (Di Sebastiano et al., 2013). As well, obese 
patients with PDAC exhibit higher losses in weight, skeletal muscle, and adipose 
tissue along with poorer survival (Dalal et al., 2012).  Even absent muscle 
wasting, low fat mass or “adipopenia” is associated with mortality in patients with 
diffuse large B-cell lymphoma treated with immunotherapy (Camus et al., 2014) 
and in patients with heart failure (Melenovsky et al., 2013), among other 
conditions. Furthermore, our longitudinal analysis of patients with advanced 
PDAC on FOLFIRINOX demonstrates equivalent mortality for patients with fat-
only loss versus patients with both fat and muscle loss, with overall 10 months 
reduced survival than patients without loss of either depot (Kays et al., 2018). 
Thus, the preponderance of clinical data point to an important role for adipose in 
PDAC cachexia and mortality. Moreover, preserving adipose tissue via 
pharmacological or genetic manipulation of lipolysis and lipogenesis protects 
muscle in other cachexia models (Das et al., 2011; Rohm et al., 2016) (Tsoli, 
Swarbrick, & Robertson, 2016), although in all of these studies multiple tissues in 
addition to adipose were affected by the intervention. 
Whether changes in tumor growth were due to reduced IL-6 or due to 
reduced substrate availability from the relative preservation of fat and muscle 
require further investigation. Conversely, whether reduced cachexia was due to 
decreased circulating IL-6 or due to other IL-6-dependent tumor properties 
including altered tumor phenotype and secretome are complex questions, which I 
am actively investigating. Indeed, tumor size did not correlate with muscle or fat 
	
	 	 120 
wasting in my investigations, suggesting that the tumor secretome may be more 
telling for the severity of cachexia rather than simply assuming that larger tumors 
are associated with increased cachexia. Notably, IL-6 has been shown to have 
importance in tumor proliferation and differentiation in vivo (ref). Regardless, 
clearly IL-6 production from tumor cells can orchestrate cachexia and this tumor 
characteristic could have diagnostic and therapeutic implications for PDAC.  
 
5.2 Metabolic Alterations in Skeletal Muscle with PDAC 
Cachexia imposes significant modifications to the normal energy demands 
in tissues, which ultimately affects metabolic homeostasis. I posit that adipose 
wasting promotes muscle dysmetabolism and atrophy and thus, strongly 
contributes to mortality. KPC tumor mice had significant changes in muscle 
metabolism and these changes were largely absent when IL-6 was deleted from 
the tumor. Lipolysis of adipose tissue resulted in elevated circulating fatty acids 
and subsequent lipid accumulation and myosteatosis in muscle of KPC tumor 
mice (Figures 2.8 and 2.9). Myosteatosis, sarcopenia and the combination are 
associated with reduced survival in one study of resectable patients with 
pancreatic and periampullary adenocarcinomas (Stretch et al., 2018), while only 
myosteatosis was associated with inflammation and reduced survival in another 
study of patients with unresectable pancreatic cancer or cholangiocarcinoma 
(Rollins et al., 2016). After a period of muscle metabolic adaptation this ultimately 
results in lipotoxicity, including metabolic derangement, cellular stress, and 
muscle wasting.  My histological and RNAseq data support this interpretation.  
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In KPC tumor mice, RNA sequencing analysis revealed differential 
expression of genes associated with IL-6 signaling, lipid metabolism, and 
glycolysis in muscle. In the epididymal fat pads, pathways related to diapedesis, 
LXR/RXR activation—important regulators of cholesterol, lipid and glucose 
homeostasis, acute phase signaling, and IL-6 signaling pathways were also 
affected. Importantly, gene expression correlated with wasting in both tissues. 
While muscle from mice with IL-6KO tumors was unaffected for mass and nearly 
normal in terms of gene expression, moderate adipose wasting and altered gene 
expression changes were clearly well established in KPC IL-6KO tumor mice. 
Thus, investigation of muscle metabolism was clearly warranted in these models.  
My investigations into muscle metabolism identified significant changes to 
branch chain amino acid (BCAA) oxidation, glycolysis and TCA Cycle function, 
and alterations in lipid metabolism especially regarding beta-oxidation and 
triacylglycerol synthesis. BCAA metabolism was increased in the muscle of KPC 
tumor mice determined by increases in expression of genes crucial for BCAA 
oxidation and transport, with concomitant increases in both plasma and muscle 
BCAA levels. BCAA metabolism is important for organismal survival during 
conditions of reduced nutrient availability and increased BCAA catabolism for use 
as an energy source has been reported with cachexia. Changes in glycolysis and 
TCA cycle function were also observed in the muscle of KPC tumor mice, 
although changes in plasma metabolites and muscle gene expression were more 
sensitive and a better indicator of cachexia than muscle metabolite 
measurements alone. Decreased plasma glucose was observed in both KPC and 
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KPC IL-6KO tumor mice. This result is similar to other studies that also report low 
blood glucose in cancer. Compared to KPC IL-6KO tumor mice, pyruvate was 
increased in the muscle of KPC tumor mice. This was accompanied by significant 
increases in PDK4 expression in KPC tumor mouse muscle, suggesting inhibition 
of the PDH complex activity and reduced entry of pyruvate into the TCA cycle. 
Typically, this would result in accumulation of lactate but interestingly muscle and 
plasma lactate levels were unchanged in KPC tumor mice and actually 
decreased in KPC IL-6KO tumor mice. Increased consumption of lactate by the 
liver for gluconeogenesis may explain the maintenance of homeostatic lactate 
levels, via the Cori Cycle (Streja, Steiner, Marliss, & Vranic, 1977). This theory is 
confounded however by the decrease in blood glucose, which may be occurring 
due to increased utilization of blood glucose by the tumor. Further investigation is 
needed especially regarding liver and tumor metabolism to increase our 
understanding of these results.   
A reduction in TCA cycle function was predicted for a number of key 
enzymes using my RNAseq data. Interestingly, plasma metabolite levels again 
were a better predictor of cachexia. While unchanged in muscle, increased 
acetate with decreases in fumurate and malate were measured in plasma. The 
increases in acyl-CoA synthetase short chain family member 2 (Acss2) and 
acetate, along with decreases in fumurate and malate suggests that acetyl-CoA 
generated from acetate metabolism may be primarily used for lipogenesis of 
accumulating fatty acids and thus, leave insufficient acetyl-CoA levels to fuel 
proper TCA Cycle function. Acetyl-CoA can also be generated from oxidation of 
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fatty acids during beta-oxidation, providing additional mechanisms for activation 
of the TCA Cycle. Therefore, impaired TCA Cycle function in muscle may also be 
indicative of aberrant muscle lipid metabolism. Indeed, I observed significant 
changes to muscle lipid metabolism. RNAseq data and IPA analysis indicated a 
decrease in multiple genes important in beta-oxidation, triacylglycerol synthesis, 
and acyl-CoA hydrolysis. These findings were further supported by increases in 
both plasma and muscle acylcarnitine levels in KPC tumor mice. Suggesting 
aberrant lipid metabolism and incomplete beta-oxidation in muscle. Moreover, 
impaired beta-oxidation was found to be central to muscle wasting in 
experimental renal cell carcinoma models, and inhibition of fatty acid oxidation 
improved body weight and muscle mass in mice (Fukawa et al., 2016). These 
results support clinical relevance of my observations here.  
 
5.3 Deletion of PKC theta Attenuates Muscle Wasting 
My results clearly implicate the importance of IL-6 signaling between fat 
and muscle, especially through sIL6R trans signaling, and the capability of 
subsequent myosteatosis to augment atrophy and dysmetabolism in muscle. 
Therefore, I postulated the existence of a common molecule in muscle that is 
affected by changes in metabolism and also has an effect on systemic 
inflammation. Soluble IL6R is associated with increased inflammation in disease 
and sIL6R is largely produced by proteolytic cleavage of membrane GP80, which 
in mice and humans is mediated by ADAM10 and ADAM17 proteases 
(Schumacher et al., 2015). PKCθ activation is a known rate-limiting step for 
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shedding of IL-6R largely through activation of ADAM10 and ADAM17 (Mullberg 
et al., 1992). Since PKCθ belongs to the nPKC family its activation is dependent 
on the presence of diacylglycerol (DAG). Muscle steatosis is correlated with 
increases in diacylglycerol (DAG), insulin resistance and increased activation of 
PKC theta (Szendroedi et al., 2014). Thus, these previous findings suggest a 
connection between adipose wasting and induction of trans-signaling via muscle-
derived sIL6R. 
Indeed, PKCθ phosphorylation was increased in muscle of KPC but not 
KPC IL-6KO tumor mice, coinciding with increased myosteatosis in the KPC tumor 
mouse muscle. Deletion of PKCθ was associated with increased survival and 
maintenance of skeletal and cardiac muscle masses in the presence of PDAC. 
Moreover, muscle force production was higher in PKCθ-/- tumor mice versus 
PKCθ+/+ tumor mice, suggesting preservation of both mass and function. PKCθ 
has been implicated in a number of other cachexia-associated diseases including 
diabetes and muscular dystrophy, where deletion of PKCθ improved muscle 
wasting in these conditions. While its relationship with protein ubiquitination is 
unknown in muscle, PKCθ has been shown to affect the ubiquitination and 
subsequent degradation via the ubiquitin proteasome of proteins in T cells 
(Gruber et al., 2009) and neurons (Upadhya, Ding, Smith, & Hegde, 2006). It is 
therefore possible that PKCθ may be affecting the ubiquitination of critical 
proteins in muscle and contributing to muscle catabolism in cachexia. These 
studies along with my findings here suggest inhibition of PKCθ is beneficial in 
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PDAC cachexia and suggests PKCθ as a novel target for improving the effects of 
pancreatic cancer.  
 
5.4 Future Directions and Limitations 
Cancer cachexia is a systemic syndrome and understanding changes to tissue 
crosstalk in the presence of a tumor is critical for designing effective treatment. 
The data provided here strongly support the targeted inhibition of IL-6R to treat 
PDAC cachexia. Pre-clinical studies document improved response to 
chemotherapy in mice with pancreatic cancer treated with anti-IL6R antibodies 
(Long et al., 2017); whether those mice also demonstrated reduced cachexia 
was not reported. An ongoing trial of the IL6R inhibitor Tocilizumab with 
gemcitabine and nab-paclitaxel in patients with advanced and metastatic disease 
might provide important insights on this approach in PDAC (I. Chen et al., 2017). 
My results add to the literature by implicating fat loss as a potential driver 
of cachexia mortality and immunomodulation in cancer (Tsoli et al., 2016), since 
fat loss was more profound and occurred earlier than muscle loss in the 
presence of a tumor. I have also identified adipose tissue as a significant source 
of IL-6 production in PDAC, greatly increasing circulating levels of IL-6 and 
systemic inflammation. These results will impact future patient therapies by 
supporting the need to monitor adipose tissue in patients with cachexia-
associated cancers. Moreover, my studies also suggest that diverse strategies 
aimed at returning metabolic homeostasis may improve the outcomes of patients 
with PDAC. For instance, the reduction or inhibition of adipose tissue lipolysis 
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would decrease circulating fatty acids and may lead to decreased myosteatosis, 
which may restore metabolic homeostasis in muscle. There already exist 
inhibitors of the enzyme adipose triglyceride lipase (Atgl) as well as Atgl ablated 
mice. Studies in have shown that inhibition or ablation of Atgl is associated with 
less cachexia in the presence of a tumor(Das et al., 2011) and decreased tumor 
growth(Zagani, El-Assaad, Gamache, & Teodoro, 2015)   
Thus, in future studies I aim to target both plasma sIL6R and muscle 
metabolism. Given the ability of PKCθ to affect both inflammation and 
dysmetabolism in muscle, I plan to utilize PKCθ-/- mice implanted with KPC 
tumors and administer anti-sIL6R agents to neutralize plasma sIL6R. Using this 
approach, I predict that a significant reduction in systemic inflammation will be 
observed coinciding with a return to metabolic homeostasis in skeletal muscle. If 
this occurs, a reduction in cachexia and an increase in survival will likely also be 
obtained. I recognize my use of a global PKCθ knockout murine model is an 
inferior approach to using a conditional muscle PKCθ knockout, however the 
current unavailability of the conditional knockout limits my studies to one genetic 
model. This approach will also provide an opportunity to investigate in detail, the 
changes to muscle metabolism occurring with PDAC in the absence of PKCθ. I 
aim to use proteomic analyses in addition with RNAseq to provide an improved 
understanding of functional results for key metabolic enzymes and pathways. I 
will focus on identifying changes in metabolites, proteins and gene expressions in 
early onset disease with or without the expression of PKCθ. This will allow me to 
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identify possible novel biomarkers to diagnose PDAC earlier, which could 
increase treatment efficacy and increase patient survival.  
Furthermore, the ability to track the IL6R from muscle to adipose tissue 
would strengthen my hypotheses. The genetic model R26-MetRS (028071, 
Jackson Laboratories) is a genetic model with a mutated methionyl-tRNA 
synthetase (MetRS), which when crossed with a tissue specific Cre-recombinase 
mouse strain, will label all the proteins synthesized in the tissue of interest with 
the mutated methionyl residue. Downstream utilization of click chemistry in 
various tissues allows for the isolation of proteins that originated within the tissue 
of interest (Takayama, Kusamori, & Nishikawa, 2019). Thus, I aim to cross the 
R26-MetRS with the HSA-Cre strains to specifically label peptides in the muscle 
proteome. These mice will then be implanted with KPC tumors and adipose 
tissue harvested and analyzed for the presence of muscle labeled IL6R. This 
approach is beneficial in two ways, the first showing that muscle IL6R trans 
locates to fat in PDAC and second, plasma from these mice can be used to 
characterize the muscle secretome in PDAC. Results from these future studies 
will greatly improve our understanding of the crosstalk between fat and muscle in 
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